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trans-3-Amino-b-lactams were evaluated as the chiral building blocks in the aza-Diels – Alder
reaction of azetidin-2-one-tethered imines with siloxydienes under Lewis acid catalysis, as a
route for the asymmetric synthesis of 2-aryl(alkyl)-2,3-dihydro-4-pyridones.
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INTRODUCTION
Diversely substituted monocyclic b-lactams occupy a cen-
tral place among medicinally important compounds due
to their diverse and interesting antibiotic activities. Con-
sequently their synthesis has been of considerable inter-
est to the synthetic community in the past few decades.1,2
Because of the recent developments using b-lactams as
synthons for several biologically active compounds, re-
search on this topic has gained tremendeous attention.3–6
Hetero Diels – Alder reactions involving imino-dienes
or imino-dienophiles are widely used for the construc-
tion of nitrogen-containing compounds.7,8 Our interest in
the use of trans-3-amino-b-lactams,9,10 as starting sub-
strates, for the preparation of potentially bioactive prod-
ucts prompted us to evaluate the combination of aza-
Diels – Alder reaction of azetidin-2-one-tethered imines
1 with siloxydienes 2 as a route to the asymmetric syn-
thesis of 2-aryl(alkyl)-2,3-dihydro-4-pyridones 3 and 4,
which are interesting heterocycles and attractive build-
ing blocks for alkaloid synthesis11–19 (Scheme 1).
RESULTS AND DISCUSSION
We applied lithium chiral ester enolate-imine condensa-
tion strategy,20–22 synthetic methodology based on the aze-
tidin-2-one nucleus: the b-lactam synthon method,23,24 to
the asymmetric synthesis of trans-3-amino-b-lactams9,10
5. Treatment of trans-3-amino-b-lactams 5a-g with a va-
riety of aldehydes 6a-k in boiling ethanol followed by
stirring in dichloromethane at room temperature in the
presence of sodium sulfate provided the corresponding
imines 1a-s (Scheme 2). Aryl and ferrocenyl imines 1a-h
and 1k-s (isolated yields vary from 59 to 91 %) were puri-
fied by recrystallization, while alkyl imines 1i-j (1H NMR
spectra calculated yields: 65 and 60 %) were generated
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in dichloromethane at room temperature, filtered, evapo-
rated to dryness and as such applied in the next reaction
step.
1-Methoxy-3-trimethylsilyloxy-1,3-butadiene11 2a
(Danishefsky's diene; TMS = trimethylsilyl) and
trans-3-(tert-butyl-dimethylsilyloxy)-1-methoxy-1,3-but
adiene12 2b (TBDMS = tert-butyl-dimethylsilyl) were
used in Diels – Alder reaction with azetidin-2-one-teth-
ered imines 1a-s as dienophiles. First we studied the
aza-Diels – Alder reaction of imine 1a with Danishef-
sky's diene 2a in the presence of equimolar (x = 100 %,
mole fraction) and a catalytic (x = 20 %) amount of vari-
ous catalysts. The cycloaddition took place at low tem-
perature (–20 °C) in acetonitrile under Lewis acid cata-
lysis. Diastereoselectivities were reasonable but the che-
mical yield of the process depended on the nature of the
Lewis acid (Table I). We found that zinc(II) iodide and
indium(III) chloride (Table I, entries 1–4) provided the
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Scheme 2. Preparation of imines 1a-s.
Scheme 1. Preparation of 3 and 4.
best chemical yields combined with the highest dia-
stereoselectivity and decided to continue our study with
a variety of imines 1 and dienes 2a-b with zinc(II) io-
dide (x = 20 %) in acetonitrile at –20 °C. The results are
presented in Table II. We studied the influence of vari-
ous groups on imine (R1 = H, PMP; R2 = aryl, ferrocenyl;
R3 = alkyl, aryl, ferrocenyl) and on diene (TMS, TBDMS)
part on diastereomeric ratio and product yield of the
reaction. Displacement of PMP group with H at the R1
position (Table II, entries 1, 20) did not influence on the
diastereomeric ratio but yield significantly dropped. Com-
bination of a variety of the substituents (Table II, entries
1-8) on phenyl ring at the R3 position with TBDMS group
in 2b generated increase in product yield and diastereo-
meric ratio, exhibiting the best diastereomeric ratio
(78:22) with R3 = 4-fluoro- and 4-nitro-phenyl (entries
4, 8). Displacement of aryl with alkyl-substituent (R3 =
cyclohexyl, tert-butyl; entries 9, 10) resulted in signifi-
cant drop in product yield and diastereomeric ratio espe-
cially with less bulky tert-butyl group. The change of the
substituents on phenyl ring at the R2 position (entries
10-16) compared with the same change at the R3 posi-
tion (entries 1-8) created more significant drop in prod-
uct yield than in diastereomeric ratio. Introducing ferro-
cenyl group at the R3 position (entry 11) resulted with
the best diastereomeric ratio (85:15) and the lowest yield
(11 %) in product formation. The best results in yield
(84 % and 79 %) and diastereomeric ratio (80:20) were
obtained with ferrocenyl group at the R2 position (entries
17 and 18) vs. no reaction with ferrocenyl group at both
R2 and R3 positions (Table II, entry 19). In order to
improve diastereomeric ratio of the reaction, we replac-
ed26,27 methyl at the C1 position of Danishefsky's diene 2a
with (1R,2S,5R)-(–)-menthyl (diene – 2c), (1S,2R,5S)-
(+)-menthyl (2d), and (1R,2S)-(–)-trans-2-phenyl-1-
cyclohexyl (2e) introducing the new chiral informations
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TABLE I. Lewis acid mediated Diels – Alder cycloaddition between
(3R,4R)-1a and 2a
Entry Lewis acid mole
fraction
3a/4a
Ratio(a)
Yield
3a/4a
1 ZnI2 20 68 : 32 92
2 ZnI2 100 66 : 34 78
3 InCl3 20 66 : 34 85
4 InCl3 100 66 : 34 85
5 LiClO4 20 67 : 33 44
6 LiClO4 100 68 : 32 36
7 AlCl3 20 62 : 38 57
8 AlCl3 100 63 : 37 67
9 TiCl4 20 62 : 38 34
10 TiCl4 100 60 : 40 34
11 In(OTf)3 20 64 : 36 31
12 In(OTf)3 100 – –
(a)The diastereomeric ratio was determined by integration of well-re-
solved signals in the 1H NMR spectra of the crude reaction mixtures
before purification and confirmed by RP-HPLC (Figure 1).
Figure 1. 1H NMR spectra of C3 Ha and Hb well-resolved proton signals on pyridone ring and RP-HPLC profile of 3a/4a diastereomeric
mixture.
on the diene part. The reaction with dienes 2c-d was per-
formed in the presence of zinc(II) iodide (x = 20 %) as
catalyst in acetonitrile at –20 °C and atmospheric pres-
sure (Table III, entries 1, 4, and 7). The reaction pro-
ceeded slower, in 72 h only 40 % of mixture of 3a/4a
was formed, but diastereomeric ratio significantly in-
creased from 68:32 (Table II, entry 1) to 86:14 (Table
III, entries 1 and 4). No difference in diastereomeric ra-
tio was observed with dienes 2c and 2d employing (+)-
vs. (–)-menthol, it seems diastereoselectivity is rather re-
gulated with menthol's sterric effect than chiral informa-
tion. Furthermore, in order to improve the reaction yield,
we combined increased pressure (8 kbar) at room tem-
perature and 100 °C (Table III, entries 2, 3; 5, 6 and 8,
9). The reaction yield increased from 63 % (room tem-
perature, 12 h) to almost quantitative (96 %, 100 °C,
12 h), while diastereomeric ratio little dropped to 83:17
at room temperature, and more significantly dropped at
100 °C (75:25) (Table III, entries 2, 3 and 5, 6).
We also investigated in the literature-described28–31
chiral ligands (e.g. commercially available (R)-, (S)-
BINOL, 2,2'-iso-propylidenebis[(4S)-4-tert-butyl]-2-ox-
azoline and 7 (Figure 2) prepared31 from amino acid L-
Ile) in combination with a variety of Lewis acids (e.g.
indium(III) chloride, titanium(IV) isopropoxide, triphen-
yl borate, copper(II) trifluoromethanesulfonate, and cop-
per(I) trifluoromethanesulfonate benzene complex) in the
Diels – Alder cycloaddition between imine 1a and diene
2b. Although under similar conditions these chiral lig-
ands exhibited extremely high asymmetric induction, the
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TABLE II. Lewis acid mediated Diels – Alder cycloaddition between imines 1a-s and dienes 2a-b
Entry Imine Diene R1 R2 R3 3/4 Ratio Yield 3/4
1 3R,4R
1a 2a PMP(a) Ph(b) Ph 3a/4a
R,R,R:S,R,R
68 : 32 92
2b 69 : 31 89
2 1b 2a PMP Ph PMP 3b/4b 66 : 34 77
2b 72 : 28 87
3 1c 2a PMP Ph 3,4-(H3CO)2-Ph 3c/4c 70 : 30 92
2b 70 : 30 91
4 1d 2a PMP Ph p-F-Ph 3d/4d 70 : 30 81
2b 78 : 22 98
5 1e 2a PMP Ph p-F3C-Ph 3e/4e 73 : 27 77
6 1f 2b PMP Ph o-O2N-Ph 3f/4f 73 : 27 59
7 1g 2b PMP Ph m-O2N-Ph 3g/4g 73 : 27 85
8 1h 2b PMP Ph p-O2N-Ph 3h/4h 78 : 22 97
9 1i 2a PMP Ph C6H11 3i/4i 60 : 40 39
2b 67 : 33 64
10 1j 2a PMP Ph C(CH3)3 3j/4j 55 : 45 44
11 1k 2a PMP Ph Fc 3k/4k 85 : 15 11
2b 67 : 33 49
12 1l 2b PMP PMP Ph 3l/4l 68 : 32 58
13 1m 2a PMP PMP PMP 3m/4m 68 : 32 55
14 1n 2a PMP 3,4-(H3CO)2-Ph Ph 3n/4n 66 : 34 76
2b 66 : 34 79
15 1o 2b PMP p-F-Ph Ph 3o/4o 72 : 28 89
16 1p 2b PMP p-F3C-Ph Ph 3p/4p 74 : 26 59
17 1q 2a
2b
PMP Fc(c) Ph 3q/4q 80 : 20
78 : 22
84
85
18 3S,4S
1q 2a PMP Fc Ph 3q/4q
S,S,S:R,S,S
80 : 20 79
19 1r 2a
2b
PMP Fc Fc 3r/4r –
–
–
–
3R,4R R,R,R:S,R,R
20 1s 2a
2b
H(d) Ph Ph 3s/4s 65 : 35
66 : 34
44
50
(a)PMP = 4-Methoxy-phenyl; (b)Ph = Phenyl; (c)Fc = Ferrocenyl; (d)PMP group in (3R,4R)-1a was removed with ceric ammonium nitrate25
observed diastereoselectivities remained reasonable (3a/4a
diastereomeric ratios varied from 56:44 to 67:33) in our
case.
Crystal Structure Determination of (2S,3'S,4'S)-3q
The crystal structure of (2S,3'S,4'S)-3q was determined in
order to establish unambiguously both absolute and rela-
tive configuration at the stereogenic center C21. The S
absolute configurations of two stereogenic centers at the
azetidin-2-one ring, C11 and C12 were determined previ-
ously,10 and in relation to them, the absolute configuration
of C21 was also found to be S. Ferrocenyl moiety and the
pyridone ring (N2-C21-C22-C23-C24-C25) are in trans-
position with respect to the C11-C12 bond with torsion
angle N2-C12-C11-C1 being 118.4(12) ° (Figure 3). The
geometrical parameters of the azetidin-2-one ring agree well
with the average values10 extracted from the Cambridge
Structural Database.32 Conformation of the pyridone ring
is a half-chair with Cremer-Pople33 parameters Q = 0.406
(14) Å, Q = 58(2) °, j = 88(2) °. The phenyl ring bound
to C12 and the p-methoxyphenyl ring bound to N1 are al-
most perfectly planar (Figure 3).
Since there are no strong proton donors, the crystal
packing of compound (2S,3'S,4'S)-3q is dominated by
weak C-H···O hydrogen bonds forming double layers
parallel with [001] plane (Figure 4). C-H···p interactions
link the layers into a 3D network. C20 interacts with
both phenyl rings via H20B and H20C atoms (symmetry
operator is in both cases 1–x, ½+y, 2–z). There are no
p···p interactions between ferrocenyl moieties and/or
phenyl rings (Figure 4).
Molecular Modelling
Semiempirical PM3 calculation method34,35 was used to
model Diels – Alder reaction of dienes with azetidin-2-
one-tethered imines catalyzed by Lewis acids. FMO anal-
ysis has revealed that the preferred regioselectivity is go-
verned by orbital symmetry and the size of coefficients. It
was assumed that for Lewis acid catalysis (using zinc(II)
iodide and indium(III) triflate as a model compounds), aze-
tidin-2-one-tethered imine acts as a bidentate ligand, co-
ordinating with metal via imine nitrogen and carbonyl ox-
ygen. Such a metal coordination determines geometrical
relationship between azetidin-2-one and imine unit, while
C4 phenyl and N1 p-methoxyphenyl substituents on aze-
tidin-2-one ring freely rotate. PM3 modelling has shown
the preferential in-plane orientation of p-methoxyphenyl
group (in respect to azetidin-2-one ring), while phenyl
group is oriented almost perpendicularly. Restricted rota-
tion of imine double bond yields two rotamers, while
phenyl substituent on the imine bond freely rotates. These
geometrical arrangements of the substituents and Lewis
acid predetermine possible modes of the diene approach
and the consequence of cycloadditions. There is a slight
preference to diene approach from the top side yielding
R-isomer, while diene approach from the bottom side
leading to S-isomer is less preferred, (Figure 5). These
computational predictions are in good agreement with ex-
perimental results, where in the most of Lewis acid cata-
lyzed reactions, R:S ratio ≈70:30 is found (Table II).
EXPERIMENTAL
Melting points were determined on a Reichert Thermovar
7905 apparatus and were not corrected. The IR spectra were
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Figure 2. Structure of chiral ligand 7.
TABLE III. The diastereomeric ratio and yield dependence on reaction temperature and pressure in Lewis acid mediated Diels – Alder
cycloaddition between imine 1a and dienes 2c-e
Entry Diene t/h T/°C p/kbar 3a/4a Ratio Yield 3a/4a
1 72 –20-RT(a) 1 86 : 14 40
2 2c 12 RT 8 83 : 17 63
3 12 100 8 75 : 25 96
4 72 –20-RT 1 86 : 14 39
5 2d 12 RT 8 81 : 19 64
6 12 100 8 71 : 29 95
7 72 –20-RT 1 79 : 21 51
8 2e 12 RT 8 73 : 27 74
9 12 100 8 68 : 32 99
(a)RT = room temperature
recorded on a Perkin Elmer Spectrum RX I FT-IR System
spectrometer (KBr pellets technique) (PerkinElmer Instru-
ments, Norwalk, CT, USA). The 1H and 13C NMR spectra
(in CDCl3 at room temperature) were measured on a Bruker
AV 300 and/or AV 600 spectrometer (Bruker BioSpin
GmbH., Rheinstetten, Germany), d in ppm relative to
tetramethylsilane as the internal reference. Microanalyses
were performed on a PE 2400 Series II CHNS/O Analyzer
(PerkinElmer Instruments, Shelton, CT, USA). Optical rota-
tions: Automatic Polarimeter AA-10 in a 1 dm cell; c in
g/100 mL (Optical Activity Ltd., Ramsey, England). HPLC
analyses were performed on a HPLC System (Dr ing. Her-
bert Knauer GmbH., Berlin, Germany) supplied with
UV/VIS WellChrom Diode Array Detector K-2800 using
Waters Nova-Pak 4 mm-Spherical C18 (reversed phase) 3.9 ×
150 mm HPLC Column (Waters Corporation, Milford, MA,
USA) operated at a room temperature and a flow rate 1
mL/min; linear gradient of water containing 0.1 %
trichloroacetic acid (solvent A) and methanol (solvent B);
100 % A, 5 min; 80 % A + 20 % B, 5 min; 50 % A + 50 %
B, 10 min; 20 % A + 80 % B, 10 min; 100 % B, 5 min. Col-
umn chromatography on silica gel 60, 70–230 mesh, 60 Å
(E. Merck, Darmstadt, Germany) was performed at room
temperature. Thin layer chromatography was carried out on
TLC aluminium sheets, 20 × 20 cm, silica gel 60 F254 and
preparative thin layer chromatography on PLC plates, 20 ×
20 cm, silica gel 60 F254, 2 mm (E. Merck). High pressure
reaction was performed using the high pressure piston-cylin-
der apparatus, in teflon cells and petroleum ether as piezo-
transmitter liquid. High resolution, positive ion mass spec-
tra were recorded on a FT/MS 2001-DD Fourier transform
mass spectrometer (Finnigan, Madison, WI, USA) equip-
ped with a 3 T superconducting magnet and a Nicolet 1280
data station, using PFTBA as standard for external calibra-
tion. LC-MS spectra were recorded on a Hewlett Packard
HP-1100 Series System (Hewlett Packard, Palo Alto,
CA, USA) equipped with a binary solvent pump, an auto-
sampler (volume injection set to 20 mL), and a mass selec-
tive detector (HP MSD) with electrospray ionization (ESI)
using Macherey-Nagel 5 mm Kromasil C18 4.0 × 250 mm
HPLC column (Macherey-Nagel GmbH & Co. KG, Düren,
Germany) operated at room temperature and a flow rate
1 mL/min; linear gradient of water containing 0.1 % formic
acid (solvent A) and methanol (solvent B); 60 % A + 40 %
B, 0 min; 5 % A + 95 % B, 10 min; 5 % A + 95 % B, 5 min;
60 % A + 40 % B, 2 min. Operating conditions of the ESI
interface in positive ion mode were: nebulizer gas (nitro-
gen) pressure 25 psig, drying gas (nitrogen) flow rate 10
L/min, drying gas temperature 350 °C, capillary voltage
4000 V. Crystal structure measurements were performed on
an Enraf Nonius CAD4 diffractometer (Bruker-Nonius,
Delft, Netherlands), using a graphite monochromated Cu
Ka (1.54179 Å) radiation at room temperature [293(2) K].
Geometrical optimizations were carried out employing
PM3 semiempirical method within Gaussian03 suite of pro-
grams, implemented on dual core Opteron 240 personal
computer under Linux OS. Full optimizations were fol-
lowed by vibrational analysis to verify that the obtained
structures are true minima on the potential surface.
Preparation of Azetidin-2-one-tethered Imines 1a-s
General Procedure. – A mixture of trans-3-amino-b-lac-
tams 5a-g and aldehydes 6a-h and 6k was dissolved in an-
hydrous ethanol (5.0 mL), heated under reflux for 12 h and
cooled; evaporated to dryness, redissolved in dichloro-
methane (5.0 mL) and stirred at room temperature over an-
hydrous sodium sulfate (100.0 mg) for additional 30 min-
utes. Sodium sulfate was filtered off, washed with dichloro-
methane (3 × 5 mL) and filtrate evaporated to dryness.
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Figure 3. ORTEP drawing of compound (2S,3'S,4'S)-3q. Thermal
ellipsoids are drawn at 50 % probability.
Figure 4. Crystal packing of compound (2S,3'S,4'S)-3q. Hydrogen
bonded chains C22-H22B ··· O1i run in [010] direction and the
3D network is completed by C-H···p interactions. Hydrogen atoms
not participating in hydrogen bonds have been omitted for clarity.
Symmetry codes: i) x, –1+y, z; ii) –x, ½+y, 2–z; iii) 1–x, ½+y,
2–z.
Imines 1a-h, 1k-q and 1s were recrystallized from a proper
solvent.
(3R,4R)-3-Benzylideneamino-1-(4-methoxyphenyl)-
4-phenylazetidin-2-one (1a). – Obtained from 5a (150.0 mg,
5.59 × 10–1 mmol) and 6a (59.3 mg, 5.59 × 10–1 mmol) as
white crystals (from dichloromethane-petroleum ether (b.p.
40–70 °C)), 147.7 mg (74 %), Rf = 0.25 (dichloromethane),
m.p. 181–182 °C; [a]D = +275.3 (c = 0.46 g/100 mL
dichloromethane); IR (KBr) nmax/cm–1: 3468, 2885, 2839,
1740, 1638, 1511, 1246, 695; 1H NMR (CDCl3) d/ppm:
3.74 (s, 3H, OCH3), 4.66 (m, 1H, C4, b-lactam), 5.18 (d,
1H, J = 1.84 Hz, C3, b-lactam), 6.80 (d, 2H, J = 9.03 Hz,
C3 and C5, PMP), 7.29 (d, 2H, J = 9.03 Hz, C2 and C6,
PMP), 7.34–7.45 (m, 8H, Ph) 7.77–7.80 (m, 2H, Ph), 8.40
(s, 1H, CH=N); 13C NMR (CDCl3) d/ppm: 55.37 (OCH3),
63.50 (C4, b-lactam), 83.59 (C3, b-lactam), 114.27 (C3 and
C5, PMP), 118.72 (C2 and C6, PMP), 126.25 (C2 and C6,
Ph), 128.59 (C4, Ph), 128.62 (C2 and C6, PhC=N), 129.16
(C3 and C5, Ph), 130.84 (C1, Ph), 131.44 (C3 and C5,
PhC=N), 135.39 (C1, PhC=N), 136.63 (C1, PMP), 156.20
(C4, PMP), 163.21 (CO), 164.75 (CH=N). Anal. Calcd. for
C23H20N2O2 (Mr = 356.43): C 77.51, H 5.66, N 7.86 %;
found: C 77.80, H 5.40, N 8.10 %.
(3R,4R)-3-(4-Methoxybenzylideneamino)-1-
(4-methoxyphenyl)-4-phenylazetidin-2-one (1b). – Obtained
from 5a (111.0 mg, 4.14 × 10–1 mmol) and 6b (56.4 mg,
4.14 × 10–1 mmol) as yellow crystals (from dichloro-
methane-petroleum ether (b.p. 40–70 °C)), 135.0 mg (85 %),
Rf = 0.25 (dichloromethane), m.p. 132–135 °C; [a]D =
+309.7 (c = 0.20 g/100 mL dichloromethane); IR (KBr)
nmax/cm–1: 3471, 1743, 1638, 1575, 1511, 1456, 1396, 1249,
1168, 1115, 838; 1H NMR (CDCl3) d/ppm: 3.74 (s, 3H,
OCH3), 3.84 (s, 3H, OCH3), 4.61 (d, 1H, J = 0.60 Hz, C4,
b-lactam), 5.15 (s, 1H, C3, b-lactam), 6.79 (d, 2H J = 9.00
Hz, C3 and C5, PMP), 6.92 (d, 2H, J = 8.64 Hz, C3 and C5,
PMP), 7.28 (d, 2H, J = 9.00 Hz, C2 and C6, PMP),
7.30-7.40 (m, 5H, Ph), 7.72 (d, 2H, J = 8.70 Hz, C2 and C6,
PMP), 8.31 (s, 1H, CH=N); 13C NMR (CDCl3) d/ppm:
55.35 (OCH3), 55.40 (OCH3), 63.71 (C4, b-lactam), 83.70
(C3, b-lactam), 114.05 (C3 and C5, PMP), 114.33 (C3 and
C5, PMP), 118.75 (C2 and C6, PMP), 126.27 (C2 and C6,
PMP), 128.40 (C1, Ph), 128.59 (C4, Ph), 129.13 (C2 and C6,
Ph), 130.29 (C3 and C5, Ph), 131.01 (C1, PMP), 136.88 (C1,
PMP), 156.24 (C4, PMP), 162.28 (C4, PMP), 163.61 (CO),
163.89 (CH=N). Anal. Calcd. for C24H22N2O3 (Mr =
386.45): C 74.59, H 5.74, N 7.25 %; found: C 74.46, H 5.55,
N 7.45 %.
(3R,4R)-3-(3,4-Dimethoxybenzylideneamino)-1-
(4-methoxyphenyl)-4-phenylazetidin-2-one (1c). – Obtained
from 5a (100.0 mg, 3.73 × 10–1 mmol) and 6c (61.9 mg,
3.73 × 10–1 mmol) as yellow crystals (from dichlorometha-
ne-petroleum ether (b.p. 40–70 °C)), 117.9 mg (76 %), Rf = 0.25
(dichloromethane), m.p. 180–182 °C; [a]D = +316.0 (c =
0.20 g/100 mL dichloromethane); IR (KBr) nmax/cm–1: 3855,
1736, 1509, 1458, 1243, 1155, 1027; 1H NMR (CDCl3)
d/ppm: 3.75 (s, 3H, OCH3), 3.93 (s, 3H, OCH3), 3.95 (s, 3H,
OCH3), 4.63 (bs, 1H, C4, b-lactam), 5.16 (d, 1H, J = 1.38
Hz, C3, b-lactam), 6.80 (d, 2H, J = 9.00 Hz, C3 and C5,
PMP), 6.88 (d, 1H, J = 8.22 Hz, C6, 3,4-(CH3O)2-Ph), 7.18
(d, 1H, J = 8.22 Hz, C5, 3,4-(CH3O)2-Ph), 7.29 (d, 2H, J =
8.94 Hz, C2 and C6, PMP), 7.30-7.40 (m, 5H, Ph), 7.49 (d,
1H, J = 1.38 Hz, C2, 3,4-(CH3O)2-Ph), 8.30 (s, 1H, CH=N);
13C NMR (CDCl3) d/ppm: 55.42 (OCH3), 55.97 (2 ×OCH3),
63.68 (C4, b-lactam), 83.60 (C3, b-lactam), 109.08 (C5,
3,4-(CH3O)2-Ph), 110.42 (C6, 3,4-(CH3O)2-Ph), 114.34 (C3
and C5, PMP), 118.75 (C2 and C6, PMP), 124.00 (C2,
3,4-(CH3O)2-Ph), 126.28 (C2 and C6, Ph), 128.63 (C4, Ph),
128.81 (C3, 3,4-(CH3O)2-Ph), 129.15 (C3 and C5, Ph),
131.00 (C1, PMP), 136.84 (C1, Ph), 149.38 (C1,
3,4-(CH3O)2-Ph), 152.05 (C4, 3,4-(CH3O)2-Ph), 156.26 (C4,
PMP), 163.65 (CO), 163.99 (CH=N). Anal. Calcd. for
C25H24N2O4 (Mr = 416.48): C 72.10, H 5.81, N 6.73 %;
found: C 72.15, H 5.88, N 6.91 %.
(3R,4R)-3-(4-Fluorobenzylideneamino)-1-
(4-methoxyphenyl)-4-phenylazetidin-2-one (1d). – Obtained
from 5a (100.0 mg, 3.73 × 10–1 mmol) and 6d (46.3 mg,
3.73 × 10–1 mmol) as yellow crystals (from dichloro-
methane-petroleum ether (b.p. 40-70 °C)), 92.6 mg (66 %),
Rf = 0.25 (dichloromethane), m.p. 143-145 °C; [a]D = +234.7
(c = 1.01 g/100 mL dichloromethane); IR (KBr) nmax/cm–1:
3855, 1736, 1638, 1602, 1511, 1394, 1250, 1234, 1151,
839, 698; 1H NMR (CDCl3) d/ppm: 3.74 (s, 3H, OCH3),
4.64 (bs, 1H, C4, b-lactam), 5.17 (d, 1H, J = 1.80 Hz, C3,
b-lactam), 6.80 (d, 2H, J = 9.03 Hz, C3 and C5, PMP), 7.11
(t, 2H, J1,2 = 8.64 Hz, C3 and C5, p-F-Ph), 7.29 (d, 2H, J =
9.03 Hz, C2 and C6, PMP), 7.39 (m, 5H, Ph), 7.78 (dd, 2H,
J1 = 8.67 Hz, J2 = 5.52 Hz, C2 and C6, p-F-Ph), 8.37 (s,
1H, CH=N); 13C NMR (CDCl3) d/ppm: 55.41 (OCH3), 63.56
(C4, b-lactam), 83.41 (C3, b-lactam), 114.33 (C3 and C5,
PMP), 115.81 (d, J = 87.40 Hz, C3 and C5, p-F-Ph), 118.76
(C2 and C6, PMP), 126.26 (C2 and C6, Ph), 128.72 (C4, Ph),
129.20 (C3 and C5, Ph), 130.60 (d, J = 35.21 Hz, C2 and
C6, p-F-Ph), 130.84 (C1, PMP), 131.80 (d, J = 2.78 Hz,
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Figure 5. PM3 optimized structure of complex of zinc(II) iodide
with azetidin-2-one-tethered imine 1a.
C1, p-F-Ph), 136.62 (C1, Ph), 156.28 (C4, PMP), 163.07
(C4, p-F-Ph), 163.19 (CO), 166.41 (CH=N). Anal. Calcd.
for C23H19FN2O2 (Mr = 374.41): C 73.78, H 5.11, N 7.48
%; found: C 74.01, H 5.26, N 7.73 %.
(3R,4R)-3-(4-Trifluoromethylbenzylideneamino)-1-
(4-methoxyphenyl)-4-phenylazetidin-2-one (1e). – Obtained
from 5a (100.0 mg, 3.73 × 10–1 mmol) and 6e (65.0 mg,
3.73 × 10–1 mmol) as yellow crystals (from dichloromethane-
petroleum ether (b.p. 40–70 °C)), 93.9 mg (59 %), Rf = 0.25
(dichloromethane), m.p. 150–152 °C; [a]D = +207.9 (c = 1.00
g/100 mL dichloromethane); IR (KBr) nmax/cm–1: 2361,
1752, 1513, 1324, 1249, 1065; 1H NMR (CDCl3) d/ppm:
3.75 (s, 3H, OCH3), 4.70 (bs, 1H, C4, b-lactam), 5.20 (bs,
1H, C3, b-lactam), 6.81 (d, 2H, J = 8.88 Hz, C3 and C5,
PMP), 7.29 (d, 2H, J = 8.88 Hz, C2 and C6, PMP), 7.32–7.42
(m, 5H, Ph), 7.68 (d, 2H, J = 7.98 Hz, C2 and C6, p-CF3-Ph),
7.90 (d, 2H, J = 7.98 Hz, C3 and C5, p-CF3-Ph), 8.46 (s,
1H, CH=N); 13C NMR (CDCl3) d/ppm: 55.43 (OCH3),
63.59 (C4, b-lactam), 83.28 (C3, b-lactam), 114.41 (C3 and
C5, PMP), 118.81 (C2 and C6, PMP), 125.23 (CF3), 125.62
(d, J = 3.58 Hz, C3 and C5, p-CF3-Ph), 126.29 (C2 and C6,
Ph), 128.79 (C3 and C5, Ph), 128.82 (C4, Ph), 129.25 (C2
and C6, p-CF3-Ph), 130.80 (C1, p-CF3-Ph), 132.94 (d, J =
33.10 Hz, C4, p-CF3-Ph), 136.52 (C1, PMP), 138.56 (C1,
Ph), 156.43 (C4, PMP), 162.75 (CO), 163.04 (CH=N).
Anal. Calcd. for C24H19F3N2O2 (Mr = 424.40): C 67.92, H
4.51, N 6.60 %; found: C 67.70, H 4.43, N 6.57 %.
(3R,4R)-1-(4-Methoxyphenyl)-3-(2-nitrobenzylideneamino)-
4-phenylazetidin-2-one (1f). – Obtained from 5a (60.0 mg,
2.24 × 10–1 mmol) and 6f (34.0 mg, 2.24 × 10–1 mmol) as
yellow crystals (from dichloromethane-petroleum ether (b.p.
40–70 °C)), 70.8 mg (79 %), Rf = 0.11 (dichloromethane),
m.p. 148–150 °C; [a]D = +264.7 (c = 0.20 g/100 mL dichloro-
methane); IR (KBr) nmax/cm–1: 3483, 1752, 1630, 1514, 1386,
1350, 1252, 1148, 826; 1H NMR (CDCl3) d/ppm: 3.75 (s, 3H,
OCH3), 4.76 (bs, 1H, C4, b-lactam), 5.21 (d, 1H, J = 1.80 Hz,
C3, b-lactam), 6.81 (d, 2H, J = 9.00 Hz, C3 and C5, PMP),
7.29 (d, 2H, J = 9.00 Hz, C2 and C6, PMP), 7.36-7.44 (m,
5H, Ph), 7.61 (t, 1H, J1,2 = 7.80 Hz, C4, Ph-NO2), 7.70 (t, 1H,
J1,2 = 7.44 Hz, C5, Ph-NO2), 8.04 (d, 1H, J = 7.80 Hz, C6,
Ph-NO2), 8.16 (d, 1H, J = 7.80 Hz, C3, Ph-NO2), 8.86 (s, 1H,
CH=N); 13C NMR (CDCl3) d/ppm: 55.42 (OCH3), 63.40
(C4, b-lactam), 83.38 (C3, b-lactam), 114.41 (C3 and C5,
PMP), 118.81 (C2 and C6, PMP), 124.43 (C3, Ph-NO2),
126.25 (C2 and C6, Ph), 128.85 (C4, Ph), 129.28 (C3 and
C5, Ph), 129.89 (C6, Ph-NO2), 130.40 (C1, Ph-NO2), 130.81
(C1, PMP), 131.38 (C4, Ph-NO2), 133.49 (C5, Ph-NO2),
136.32 (C1, Ph), 148.50 (C2, Ph-NO2), 156.43 (C4, PMP),
160.64 (CH=N), 162.38 (CO). Anal. Calcd. for C23H19N3O4
(Mr = 401.42): C 68.82, H 4.77, N 10.46 %; found: C 68.89,
H 4.68, N 10.34 %.
(3R,4R)-1-(4-Methoxyphenyl)-3-(3-nitrobenzylideneamino)-
4-phenylazetidin-2-one (1g). – Obtained from 5a (60.0 mg,
2.24 × 10–1 mmol) and 6g (34.0 mg, 2.24 × 10–1 mmol) as
yellow crystals (from dichloromethane-petroleum ether (b.p.
40–70 °C)), 80.0 mg (89 %), Rf = 0.19 (dichloromethane),
m.p. 136–137 °C; [a]D = +306.8 (c = 0.20 g/100 mL di-
chloromethane); IR (KBr) nmax/cm–1: 3463, 2956, 1736,
1639, 1528, 1511, 1459, 1396, 1348, 1248, 835; 1H NMR
(CDCl3) d/ppm: 3.75 (s, 3H, OCH3), 4.23 (bs, 1H, C4,
b-lactam), 5.22 (bs, 1H, C3, b-lactam), 6.81 (d, 2H, J = 9.00
Hz, C3 and C5, PMP), 7.29 (d, 2H, J = 9.00 Hz, C2 and C6,
PMP), 7.35–7.45 (m, 5H, Ph), 7.62 (t, 1H, J1,2 = 7.80 Hz,
C5, Ph-NO2), 8.10 (d, 1H, J = 7.80 Hz, C6, Ph-NO2), 8.30
(d, 1H, J = 7.20 Hz, C4, Ph-NO2), 8.50 (s, 1H, CH=N), 8.66
(s, 1H, C2, Ph-NO2); 13C NMR (CDCl3) d/ppm: 55.42
(OCH3), 63.55 (C4, b-lactam), 82.96 (C3, b-lactam), 114.40
(C3 and C5, PMP), 118.81 (C2 and C6, PMP), 123.12 (C4,
Ph-NO2), 125.70 (C2, Ph-NO2), 126.28 (C2 and C6, Ph),
128.87 (C4, Ph), 129.27 (C3 and C5, Ph), 129.70 (C5,
Ph-NO2), 130.70 (C1, PMP), 134.09 (C6, Ph-NO2), 136.39
(C1, Ph), 137.12 (C1, Ph-NO2), 148.63 (C3, Ph-NO2),
156.44 (C4, PMP), 161.81 (CH=N), 162.50 (CO). Anal.
Calcd. for C23H19N3O4 (Mr = 401.42): C 68.82, H 4.77, N
10.46 %; found: C 68.79, H 4.55, N 10.24 %.
(3R,4R)-1-(4-Methoxyphenyl)-3-(4-nitrobenzylideneamino)-
4-phenylazetidin-2-one (1h). – Obtained from 5a (60.0 mg,
2.24 × 10–1 mmol) and 6h (34.0 mg, 2.24 × 10–1 mmol) as
yellow crystals (from dichloromethane-petroleum ether (b.p.
40–70 °C)), 73.2 mg (81 %), Rf = 0.11 (dichloromethane),
m.p. 170–172 °C; [a]D = +324.7 (c = 0.20 g/100 mL di-
chloromethane); IR (KBr) nmax/cm–1: 3449, 1736, 1702,
1638, 1509, 1499, 1458, 1347, 1301, 1252, 828; 1H NMR
(CDCl3) d/ppm: 3.75 (s, 3H, OCH3), 4.73 (bs, 1H, C4,
b-lactam), 5.22 (d, 1H, J = 1.20 Hz, C3, b-lactam), 6.81 (d,
2H, J = 9.00 Hz, C3 and C5, PMP), 7.29 (d, 2H, J = 9.00
Hz, C2 and C6, PMP), 7.35–7.45 (m, 5H, Ph), 7.96 (d, 2H, J
= 8.40 Hz, C2 and C6, Ph-NO2), 8.28 (d, 2H, J = 8.40 Hz,
C3 and C5, Ph-NO2), 8.50 (s, 1H, CH=N); 13C NMR
(CDCl3) d/ppm: 55.42 (OCH3), 63.56 (C4, b-lactam), 83.20
(C3, b-lactam), 114.43 (C3 and C5, PMP), 118.81 (C2 and
C6, PMP), 123.87 (C3 and C5, Ph-NO2), 126.28 (C2 and
C6, Ph), 128.90 (C4, Ph), 129.26 (C2 and C6, Ph-NO2),
129.28 (C3 and C5, Ph), 130.70 (C1, PMP), 136.37 (C1, Ph),
140.79 (C1, Ph-NO2), 149.49 (C4, Ph-NO2), 156.49 (C4,
PMP), 162.08 (CH=N), 162.37 (CO). Anal. Calcd. for
C23H19N3O4 (Mr = 401.42): C 68.82, H 4.77, N 10.46 %;
found: C 68.58, H 4.50, N 10.19 %.
(3R,4R)-3-Cyclohexylmethylideneamino-1-
(4-methoxyphenyl)-4-phenylazetidin-2-one (1i). – Obtained
from 5a (40.0 mg, 1.49 × 10–1 mmol) and 6i (16.7 mg, 1.49 ×
10–1 mmol) in dichloromethane stirring at room temperature
over anhydrous sodium sulfate (50.0 mg) for 4 h. Sodium sul-
fate was filtered off, washed with dichloromethane (3 × 5 mL)
and filtrate evaporated to dryness. Raw product (50.2 mg, 1H
NMR spectra calculated yield of 1i – 65 %) was used directly
in the Diels-Alder reaction. 1H NMR (CDCl3) d/ppm: 1.20–1.40
(m, 5H, cyclohexyl), 1.60–1.90 (m, 6H, cyclohexyl), 3.74 (s,
3H, OCH3), 4.39 (bs, 1H, C4, b-lactam), 5.04 (d, 1H, J =
1.75 Hz, C3, b-lactam), 6.78 (d, 2H, J = 9.00 Hz, C3 and C5,
PMP), 7.24 (d, 2H, J = 9.00 Hz, C2 and C6, PMP), 7.30–7.40
(m, 5H, Ph), 7.69 (d, 1H, J = 5.00 Hz, CH=N); 13C NMR
(CDCl3) d/ppm: 25.36 (C2 and C6, cyclohexyl), 25.88 (C3
and C5, cyclohexyl), 29.40 (C4, cyclohexyl), 43.88 (C1,
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cyclohexyl), 55.37 (OCH3), 63.38 (C4, b-lactam), 83.09 (C3,
b-lactam), 114.25 (C3 and C5, PMP), 118.69 (C2 and C6,
PMP), 126.23 (C2 and C6, Ph), 128.61 (C4, Ph), 129.12 (C3
and C5, Ph), 130.85 (C1, Ph), 136.73 (C1, PMP), 156.15
(C4, PMP), 163.43 (CO), 173.93 (CH=N). Mass Spectra
(MS) for C23H26N2O2 (Mr = 362.47): calcd. m/z [M+H]+
363.206704, found 363.199878.
(3R,4R)-1-(4-Methoxyphenyl)-3-
(2,2-dimethylpropylideneamino)-4-phenylazetidin-2-one (1j). –
Obtained from 5a (40.0 mg, 1.49 × 10–1 mmol) and 6j (12.8
mg, 1.49 × 10–1 mmol) in dichloromethane stirring at room
temperature over anhydrous sodium sulfate (50.0 mg) for 4 h.
Sodium sulfate was filtered off, washed with dichloromethane
(3 × 5 mL) and filtrate evaporated to dryness. Raw product
(46.2 mg, 1H NMR spectra calculated yield of 1j – 60 %) was
used directly in the Diels-Alder reaction. 1H NMR (CDCl3)
d/ppm: 1.10 (s, 9H, 3 × CH3), 3.74 (s, 3H, OCH3), 4.39 (dd,
1H, J1 = 1.80 Hz, J2 = 1.00 Hz, C3, b-lactam), 5.04 (d, 1H, J =
1.90 Hz, C4, b-lactam), 6.78 (d, 2H, J = 9.00 Hz, C3 and C5,
PMP), 7.23 (d, 2H, J = 9.00 Hz, C2 and C6, PMP), 7.30–7.40
(m, 5H, Ph), 7.69 (d, 1H, J = 0.90 Hz, CH=N); 13C NMR
(CDCl3) d/ppm: 26.76 (3 × CH3), 29.67 (C(CH3)3), 55.38
(OCH3), 63.38 (C4, b-lactam), 83.09 (C3, b-lactam), 114.24
(C3 and C5, PMP), 118.66 (C2 and C6, PMP), 126.24 (C2
and C6, Ph), 128.58 (C4, Ph), 129.11 (C3 and C5, Ph),
130.93 (C1, Ph), 136.82 (C1, PMP), 156.11 (C4, PMP),
163.58 (CO), 176.68 (CH=N). MS for C21H24N2O2 (Mr =
336.44): calcd. m/z [M+H]+ 337,191054, found 337,198083.
(3R,4R)-3-Ferrocenylmethylideneamino-1-
(4-methoxyphenyl)-4-phenylazetidin-2-one (1k). – Obtained
from 5a (100.0 mg, 3.73 × 10–1 mmol) and 6k (79.8 mg, 3.73
× 10–1 mmol) as red crystals (from petroleum ether (b.p.
40–70 °C)), 109.7 mg (63 %), Rf = 0.25 (dichloromethane),
m.p. 167-168 °C; [a]D = +314.3 (c = 1.00 g/100 mL di-
chloromethane); IR (KBr) nmax/cm–1: 2928, 1736, 1702,
1458, 1347, 1253, 828; 1H NMR (CDCl3) d/ppm: 3.74 (s,
3H, OCH3), 4.23 (s, 5H, Fc), 4.28 (s, 1H, Fc), 4.41-4.45 (m,
2H, Fc), 4.49 (bs, 1H, C4, b-lactam), 4.61 (m, 1H, Fc), 4.77
(m, 1H, Fc), 5.14 (d, 1H, J = 1.41 Hz, C3, b-lactam), 6.79
(d, 2H, J = 9.06 Hz, C3 and C5, PMP), 7.28 (d, 2H, J = 9.06
Hz, C2 and C6, PMP), 7.38–7.40 (m, 5H, Ph), 8.26 (s, 1H,
CH=N); 13C NMR (CDCl3) d/ppm: 55.37 (OCH3), 63.49
(C4, b-lactam), 68.16, 69.56, 71.09, 71.30 and 73.15 (Fc),
79.08 (C1, Fc), 83.88 (C3, b-lactam), 114.25 (C3 and C5,
PMP), 118.68 (C2 and C6, PMP), 126.15 (C2 and C6, Ph),
128.55 (C4, Ph), 129.13 (C3 and C5, Ph), 130.92 (C1, Ph),
136.84 (C1, PMP), 156.11 (C4, PMP), 163.44 (CO), 165.46
(CH=N). Anal. Calcd. for C27H24FeN2O2 (Mr = 464.35): C
69.84, H 5.21, N 6.03 %; found: C 69.65, H 5.13, N 6.21 %.
(3R,4R)-3-Benzylideneamino-1,4-bis(4-
methoxyphenyl)azetidin-2-one (1l). – Obtained from 5b (100.0
mg, 3.35 × 10–1 mmol) and 6a (35.6 mg, 3.35 × 10–1 mmol)
as white crystals (from dichloromethane-petroleum ether (b.p.
40–70 °C)), 83.0 mg (64 %), Rf = 0.36 (dichloromethane),
m.p. 163–164 °C; [a]D = +284.4 (c = 0.20 g/100 mL dichlo-
romethane); IR (KBr) nmax/cm–1: 3855, 1736, 1637, 1510,
1395, 1246, 1168, 836; 1H NMR (CDCl3) d/ppm: 3.74 (s,
3H, OCH3), 3.80 (s, 3H, OCH3), 4.63 (m, 1H, C4, b-lac-
tam), 5.13 (d, 1H, J = 1.70 Hz, C3, b-lactam), 6.80 (d, 2H,
J = 9.00 Hz, C3 and C5, PMP), 6.91 (d, 2H, J = 8.70 Hz,
C3 and C5, PMP), 7.24–7.36 (m, 4H, 2 × C2 and 2 × C6,
PMP), 7.38–7.44 (m, 3H, Ph), 7.77 (dd, 2H, J1 = 7.60 Hz,
J2 = 1.80 Hz, Ph), 8.39 (s, 1H, CH=N); 13C NMR (CDCl3)
d/ppm: 55.30 (OCH3), 55.39 (OCH3), 63.21 (C4, b-lactam),
83.74 (C3, b-lactam), 114.27 (C3 and C5, PMP), 114.56
(C3 and C5, PMP), 118.78 (C2 and C6, PMP), 127.59 (C2
and C6, PMP), 128.50 (C1, PMP), 128.58 (C2 and C6, Ph),
128.62 (C3 and C5, Ph), 130.90 (C1, PMP), 131.40 (C4,
Ph), 135.45 (C1, Ph), 156.18 (C4, PMP), 159.89 (C4,
PMP), 163.36 (CO), 164.61 (CH=N). Anal. Calcd. for
C24H22N2O3 (Mr = 386.45): C 74.59, H 5.74, N 7.25 %;
found: C 74.34, H 5.96, N 7.36 %.
(3R,4R)-3-(4-Methoxybenzylideneamino)-1,4-bis
(4-methoxyphenyl)azetidin-2-one (1m). – Obtained from 5b
(100.0 mg, 3.35 × 10–1 mmol) and 6b (45.6 mg, 3.35 × 10–1
mmol) as yellow crystals (from dichloromethane-petroleum
ether (b.p. 40–70 °C)), 96.0 mg (69 %), Rf = 0.25 (dichloro-
methane), m.p. 182–184 °C; [a]D = +364.3 (c = 0.20 g/100
mL dichloromethane); IR (KBr) nmax/cm–1: 3458, 1736, 1607,
1511, 1442, 1306, 1248, 1167, 1150, 843, 831; 1H NMR
(CDCl3) d/ppm: 3.74 (s, 3H, OCH3), 3.80 (s, 3H, OCH3),
3.84 (s, 3H, OCH3), 4.59 (d, 1H, J = 0.50 Hz, C4, b-lactam),
5.10 (s, 1H, C3, b-lactam), 6.79 (d, 2H, J = 9.00 Hz, C3 and
C5, PMP), 6.91 (d, 2H, J = 8.20 Hz, C3 and C5, PMP), 6.92
(d, 2H, J = 8.50 Hz, C3 and C5, PMP), 7.28 (d, 2H, J = 9.00
Hz, C2 and C6, PMP), 7.32 (d, 2H, J = 8.50 Hz, C2 and C6,
PMP), 7.71 (d, 2H, J = 8.60 Hz, C2 and C6, PMP), 8.31 (s,
1H, CH=N); 13C NMR (CDCl3) d/ppm: 55.31 (OCH3),
55.36 (OCH3), 55.42 (OCH3), 63.41 (C4, b-lactam), 83.83
(C3, b-lactam), 114.06 (C3 and C5, PMP), 114.33 (C3 and
C5, PMP), 114.59 (C3 and C5, PMP), 118.81 (C2 and C6,
PMP), 127.60 (C2 and C6, PMP), 128.57 (C1, PMP), 128.76
(C1, PMP), 130.28 (C2 and C6, PMP), 131.07 (C1, PMP),
156.23 (C4, PMP), 159.92 (C4, PMP), 160.07 (C4, PMP),
162.27 (CO), 163.76 (CH=N). Anal. Calcd. for C25H24N2O4
(Mr = 416.48): C 72.10, H 5.81, N 6.73 %; found: C 71.95,
H 5.90, N 6.83 %.
(3R,4R)-3-(4-Benzylideneamino)-4-(3,4-dimethoxyphenyl)-
1-(4-methoxyphenyl)azetidin-2-one (1n). – Obtained from
5c (100.0 mg, 3.05 × 10–1 mmol) and 6a (32.2 mg, 3.05 ×
10–1 mmol) as white crystals (from dichloromethane-petro-
leum ether (b.p. 40–70 °C)), 93.7 mg (74 %), Rf = 0.47 (di-
chloromethane), m.p. 172–174 °C; [a]D = +284.4 (c = 0.20
g/100 mL dichloromethane); IR (KBr) nmax/cm–1: 3855,
1748, 1636, 1512, 1460, 1251, 1139, 1027, 834; 1H NMR
(CDCl3) d/ppm: 3.75 (s, 3H, OCH3), 3.84 (s, 3H, OCH3),
3.88 (s, 3H, OCH3), 4.67 (bs, 1H, C4, b-lactam), 5.12 (bs,
1H, C3, b-lactam), 6.80 (d, 2H, J = 8.90 Hz, C3 and C5,
PMP), 6.88 (s, 1H, C2, 3,4-(CH3O)2-Ph), 6.75–6.97 (m,
1H, C6, 3,4-(CH3O)2-Ph), 6.97 (d, 1H, J = 8.20 Hz, C5,
3,4-(CH3O)2-Ph), 7.30 (d, 2H, J = 8.90 Hz, C2 and C6,
PMP), 7.40-7.45 (m, 3H, Ph), 7.79 (d, 2H, J = 7.60 Hz, C2
and C6, Ph), 8.41 (s, 1H, CH=N); 13C NMR (CDCl3)
d/ppm: 55.38 (OCH3), 55.91 (OCH3), 55.98 (OCH3), 63.55
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(C4, b-lactam), 83.66 (C3, b-lactam), 108.83 (C6,
3,4-(CH3O)2-Ph), 111.49 (C5, 3,4-(CH3O)2-Ph), 114.26
(C3 and C5, PMP), 118.76 (C2 and C6, PMP), 118.86 (C2,
3,4-(CH3O)2-Ph), 128.58 (C2 and C6, Ph), 128.63 (C3 and
C5, Ph), 128.97 (C1, 3,4-(CH3O)2-Ph), 130.92 (C1, PMP),
131.44 (C4, Ph), 136.84 (C1, Ph), 149.30 (C3,
3,4-(CH3O)2-Ph), 149.62 (C4, 3,4-(CH3O)2-Ph), 156.22
(C4, PMP), 163.39 (CO), 164.71 (CH=N). Anal. Calcd. for
C25H24N2O4 (Mr = 416.48): C 72.10, H 5.81, N 6.73 %;
found: C 71.98, H 6.03, N 6.80 %.
(3R,4R)-3-Benzylideneamino-4-(4-fluorophenyl)-1-
(4-methoxyphenyl)azetidin-2-one (1o). – Obtained from 5d
(100.0 mg, 3.49 × 10–1 mmol) and 6a (37.0 mg, 3.49 × 10–1
mmol) as white crystals (from ethanol), 115.8 mg (89 %), Rf
= 0.54 (dichloromethane), m.p. 176-178 °C; [a]D = +269.7
(c = 0.20 g/100 mL dichloromethane); IR (KBr) nmax/cm–1:
3855, 3752, 3678, 3651, 3630, 1752, 1637, 1509, 1251,
1231; 1H NMR (CDCl3) d/ppm: 3.75 (s, 3H, OCH3), 4.63
(bs, 1H, C4, b-lactam), 5.17 (d, 1H, J = 1.70 Hz, C3,
b-lactam), 6.81 (d, 2H, J = 9.00 Hz, C3 and C5, PMP), 7.08
(t, 2H, J1,2 = 8.60 Hz, C3 and C5, p-F-Ph), 7.26 (d, 2H, J =
9.00 Hz, C2 and C6, PMP), 7.35-7.50 (m, 5H, Ph), 7.78 (dd,
2H, J1 = 7.60 Hz, J2 = 1.80 Hz, C2 and C6, p-F-Ph), 8.41 (s,
1H, CH=N); 13C NMR (CDCl3) d/ppm: 55.41 (OCH3),
62.92 (C4, b-lactam), 83.58 (C3, b-lactam), 114.36 (C3 and
C5, PMP), 116.22 (d, J = 21.71 Hz, C3 and C5, p-F-Ph),
118.73 (C2 and C6, PMP), 127.95 (C2 and C6, Ph), 128.06
(C3 and C5, Ph), 128.63 (d, J = 3.80 Hz, C2 and C6,
p-F-Ph), 130.65 (C1, PMP), 131.51 (C4, Ph), 132.44 (C1,
p-F-Ph), 135.36 (C1, Ph), 156.33 (C4, PMP), 161.18 (CO),
163.77 (d, J = 105.50 Hz, C4, p-F-Ph), 164.81 (CH=N).
Anal. Calcd. for C23H19FN2O2 (Mr = 374.41): C 73.78, H
5.11, N 7.48 %; found: C 74.01, H 5.36, N 7.73 %.
(3R,4R)-3-Benzylideneamino-4-(4-trifluoromethylphenyl)-1-
(4-methoxyphenyl)azetidin-2-one (1p). – Obtained from 5e
(100.0 mg, 2.97 × 10–1 mmol) and 6a (31.5 mg, 2.97 × 10–1
mmol) as white crystals (from ethanol), 97.1 mg (77 %), Rf
= 0.71 (dichloromethane), m.p. 156-158 °C; [a]D = +368.9
(c = 0.20 g/100 mL dichloromethane); IR (KBr) nmax/cm–1:
1741, 1637, 1511, 1326, 1248, 1170, 1126, 1113, 1081,
1066, 830; 1H NMR (CDCl3) d/ppm: 3.76 (s, 3H, OCH3),
4.65 (bs, 1H, C4, b-lactam), 5.26 (bs, 1H, C3, b-lactam),
6.82 (d, 2H, J = 8.90 Hz, C3 and C5, PMP), 7.25 (d, 2H, J =
8.80 Hz, C2 and C6, PMP), 7.47-7.41 (m, 3H, Ph), 7.53 (d,
2H, J = 8.00 Hz, C3 and C5, p-CF3-Ph), 7.66 (d, 2H, J =
8.00 Hz, C2 and C6, p-CF3-Ph), 7.79 (d, 2H, J = 7.10 Hz,
C2 and C6, Ph), 8.41 (s, 1H, CH=N); 13C NMR (CDCl3)
d/ppm: 55.43 (OCH3), 62.95 (C4, b-lactam), 83.40 (C3,
b-lactam), 114.47 (C3 and C5, PMP), 118.68 (C2 and C6,
PMP), 125.23 (CF3), 126.22 (C2 and C6, p-CF3-Ph), 126.59
(C3 and C5, p-CF3-Ph), 128.65 (C2 and C6, Ph), 128.69 (C3
and C5, Ph), 130.48 (C4, Ph), 130.94 (d, J = 32.90 Hz, C4,
p-CF3-Ph), 131.63 (C1, PMP), 135.26 (C1, Ph), 140.84 (C1,
p-CF3-Ph), 156.47 (C4, PMP), 162.78 (CO), 165.10
(CH=N). Anal. Calcd. for C24H19F3N2O2 (Mr = 424.40): C
67.92, H 4.51, N 6.60 %; found: C 67.60 H 4.35, N 6.61 %.
(3R,4R)-3-Benzylideneamino-4-ferrocenyl-1-
(4-methoxyphenyl)azetidin-2-one ((3R,4R)-1q). – Obtained
from (3R,4R)-5f (90.0 mg, 2.39 × 10–1 mmol) and 6a (25.4
mg, 2.39 × 10–1 mmol) as brown crystals (from dichloro-
methane and petroleum ether (b.p. 40-70 °C)), 67.3 mg (61
%), Rf = 0.28 (dichloromethane), m.p. 165-167 °C; [a]D =
+342.7 (c = 0.20 g/100 mL dichloromethane); IR (KBr)
nmax/cm–1: 3855, 3752, 3650, 3630, 3449, 1743, 1636, 1511,
1388, 1246; 1H NMR (CDCl3) d/ppm: 3.74 (s, 3H, OCH3),
4.24 (s, 5H, Fc), 4.27 (m, 2H, Fc), 4.32 (d, 1H, J = 1.07 Hz,
C4, b-lactam), 4.43 (s, 1H, Fc), 4.99 (d, 1H, J = 1.30 Hz, C3,
b-lactam), 5.12 (s, 1H, Fc), 6.80 (d, 2H, J = 8.85 Hz, C3 and
C5, PMP), 7.34 (d, 2H, J = 9.06 Hz, C3 and C5, PMP), 7.44
(m, 3H, Ph), 7.84 (m, 2H, Ph), 8.68 (s, CH=N); 13C NMR
(CDCl3) d/ppm: 55.41 (OCH3), 60.93 (C4, b-lactam), 66.44,
68.22, 68.63, 69.70 and 70.66 (Fc), 80.81 (C3, b-lactam),
83.12 (C1, Fc), 114.24 (C3 and C5, PMP), 119.11 (C2 and
C6, PMP), 128.54 (C2 and C6, Ph), 128.67 (C3 and C5,
PMP), 130.96 (C1, Ph), 131.39 (C4, Ph), 135.73 (C1, PMP),
156.34 (C4, PMP), 163.77 (CO), 163.89 (CH=N). Anal.
Calcd. for C27H24FeN2O2 (Mr = 464.35): C 69.84, H 5.21, N
6.03 %; found: C 69.65, H 5.02, N 5.90 %.
(3S,4S)-3-Benzylideneamino-4-ferrocenyl-1-
(4-methoxyphenyl)azetidin-2-one ((3S,4S)-1q). – Obtained from
(3S,4S)-5f (75.0 mg, 1.99 × 10–1 mmol) and 6a (21.2 mg,
1.99 × 10–1 mmol) as brown crystals (from ethyl acetate and
petroleum ether (b.p. 40–70 °C)), 72.6 mg (79 %), Rf = 0.28
(dichloromethane), m.p. 166–167 °C; [a]D = –343.05 (c =
0.20 g/100 mL dichloromethane); IR (KBr) nmax/cm–1: 3630,
3448, 1743, 1637, 1511, 1246; 1H NMR (CDCl3) d/ppm:
3.74 (s, 3H, OCH3), 4.24 (s, 5H, Fc), 4.27 (m, 2H, Fc), 4.32
(d, 1H, J = 1.07 Hz, C4, b-lactam), 4.43 (s, 1H, Fc), 4.99 (d,
1H, J = 1.30 Hz, C3, b-lactam), 5.12 (s, 1H, Fc), 6.80 (d,
2H, J = 8.85 Hz, C3 and C5, PMP), 7.34 (d, 2H, J = 9.06
Hz, C3 and C5, PMP), 7.44 (m, 3H, Ph), 7.84 (m, 2H, Ph),
8.68 (s, CH=N); 13C NMR (CDCl3) d/ppm: 55.42 (OCH3),
60.93 (C4, b-lactam), 66.44, 68.23, 68.64, 69.71 and 70.67
(Fc), 80.82 (C3, b-lactam), 83.13 (C1, Fc), 114.24 (C3 and
C5, PMP), 119.11 (C2 and C6, PMP), 128.55 (C2 and C6,
Ph), 128.68 (C3 and C5, PMP), 130.98 (C1, Ph), 131.40 (C4,
Ph), 135.74 (C1, PMP), 156.33 (C4, PMP), 163.76 (CO), 163.89
(CH=N). Anal. Calcd. for C27H24FeN2O2 (Mr = 464.35): C
69.84, H 5.21, N 6.03 %; found: C 69.82, H 5.28, N 6.30 %.
(3S,4S)-4-Ferrocenyl-3-ferrocenylmethylideneamino-1-
(4-methoxyphenyl)azetidin-2-one (1r). – Obtained from 5f
(50.0 mg, 1.33 × 10–1 mmol) and 6k (28.5 mg, 1.33 × 10–1
mmol). Raw product (69.5 mg, 1H NMR spectra calculated
yield of 1r – 91 %) was used directly in the Diels-Alder re-
action. IR (KBr) nmax/cm–1: 3432, 1742, 1629, 1511, 1246;
1H NMR (CDCl3) d/ppm: 3.74 (s, 3H, OCH3), 4.23 (s, 5H,
Fc), 4.25 (s, 5H, Fc), 4.27 (s, 1H, Fc), 4.29 (s, 1H, Fc),
4.41-4.45 (m, 4H, Fc), 4.68 (bs, 1H, C4, b-lactam), 4.80 (s,
1H, Fc), 4.93 (s, 1H, Fc), 4.98 (s, 1H, C3, b-lactam), 6.79
(d, 2H, J = 8.54 Hz, C3 and C5, PMP), 7.32 (d, 2H, J =
8.54 Hz, C2 and C6, PMP), 8.51 (s, 1H, CH=N); 13C NMR
(CDCl3) d/ppm: 55.42 (OCH3), 60.80 (C4, b-lactam),
66.41, 68.09, 68.35, 68.62, 69.29, 69.46, 69.64, 70.64,
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70.88 and 71.10 (Fc), 79.83 (C1, Fc), 81.48 (C3, b-lactam),
83.43 (C1, Fc), 114.23 (C3 and C5, PMP), 119.03 (C2 and
C6, PMP), 131.11 (C1, PMP), 156.23 (C4, PMP), 163.89
(CO), 164.61 (CH=N). MS for C31H28Fe2N2O2 (Mr = 572.28):
calcd. m/z [M+H]+ 571.075906, found 571.077821.
(3R,4R)-3-Benzylideneamino-4-phenylazetidin-2-one (1s).
– Obtained from 5g (42.0 mg, 2.59 × 10–1 mmol) and 6a
(27.5 mg, 2.59 × 10–1 mmol) as white crystals (from di-
chloromethane and petroleum ether (b.p. 40-70 °C)), 56.5
mg (87 %), Rf = 0.25 (dichloromethane), m.p. 142-144 °C;
[a]D = +22.0 (c = 1.00 g/100 mL dichloromethane); IR
(KBr) nmax/cm–1: 3448, 1752, 1702, 1686, 1655, 1628,
1560, 1364, 691; 1H NMR (CDCl3) d/ppm: 4.62 (bs, 1H,
C4, b-lactam), 4.93 (d, 1H, J = 1.50 Hz, C3, b-lactam),
6.45 (bs, 1H, NH), 7.30-7.50 (m, 8H, Ph), 7.73–7.80 (m,
2H, Ph), 8.37 (s, 1H, CH=N); 13C NMR (CDCl3) d/ppm:
59.88 (C4, b-lactam), 84.60 (C3, b-lactam), 125.89 (C2 and
C6, Ph), 128.50 (C4, Ph), 128.61 (C2 and C6, Ph; C4, Ph),
128.93 (C3 and C5, Ph), 131.42 (C3 and C5, Ph), 135.46
(C1, Ph), 138.59 (C1, Ph), 164.43 (CH=N), 167.17 (CO).
Anal. Calcd. for C16H14N2O (Mr = 250.30): C 76.78, H
5.64, N 11.19 %; found: C 76.80, H 5.38, N 11.23 %.
Preparation of 2-Aryl(alkyl)-2,3-dihydro-4-pyridones
3a-s/4a-s
General Procedure. – To a suspension of Lewis acid
(zinc(II) iodide, 0.2 mmol) in anhydrous acetonitrile (0.5
mL), a solution of imines 1a-s (1.0 mmol) in acetonitrile
(1.0 mL) was added dropwise under stirring for 15 minutes
at –20 oC. To the reaction mixture dienes 2a-e (1.1 mmol)
were added, and the mixture was left under stirring for 7 h
at –20 oC. The reaction mixture was poured onto ethyl ace-
tate (20 mL) containing saturated solution of sodium bicar-
bonate (10 mL), the product mixture was further extracted
with ethyl acetate (2 × 20 mL), combined extracts (60 mL)
were dried over anhydrous sodium sulfate, filtered and fil-
trate evaporated to dryness. Product mixtures were isolated
by a silica gel column chromatography using a mixture of
ethyl acetate-hexane in ratio 1 mL : 1 mL containing
triethylamine (0.1 mL) (eluens-A), ethyl acetate-hexane in
ratio 2 mL : 1 mL, containing triethylamine (0.1 mL)
(eluens-B), or a mixture of ethyl acetate-petroleum ether in
ratio 3:1 (eluens-C) as eluens.
(2R/2S)-1-[trans-(3'R,4'R)-1'-(4-Methoxyphenyl)-2'-oxo-4'-
phenylazetidin-3'-yl]-2-phenyl-1,2,3,4-tetrahydropyridin-4-one
(3a/4a). – Obtained from (3R,4R)-1a (100.0 mg, 2.81 × 10–1
mmol), diene 2a (62.0 mg, 3.09 × 10–1 mmol) and zinc(II)
iodide (17.8 mg, 5.62 × 10–2 mmol) as a diastereomeric mix-
ture 3a/4a, 109.7 mg (92 %), Rf = 0.25 (eluens-A). RP-HPLC
analysis of diastereomeric mixture showed ratio of 3a/4a –
68:32 % (3a, 24.38 min and 4a, 24.71 min). LC-MS for
C27H24N2O3 (Mr = 424.5019): calcd. m/z [M+H]+ 425.50,
found 425.20 (3a, 10.56 min) and 425.20 (4a, 10.90 min).
Diastereomeric mixture of 3a/4a was separated by a pre-
parative thin layer chromatography using a mixture of hex-
ane-isopropanol-triethylamine in ratio 45:4:1.
(2R)-1-[trans-(3'R,4'R)-1'-(4-Methoxyphenyl)-2'-oxo-4'-
phenylazetidin-3'-yl]-2-phenyl-1,2,3,4-tetrahydropyridin-4-one
(3a). – 74.6 mg; m.p. 103-105 °C; [a]D = –284.0 (c = 0.32
g/100 mL dichloromethane); IR (KBr) nmax/cm–1: 3449,
1752, 1654, 1648, 1594, 1512, 1249, 830, 699; 1H NMR
(CDCl3) d/ppm: 2.67 (dd, 1H, J1 = 16.50 Hz, J2 = 6.40 Hz,
C3, THPO), 3.06 (dd, 1H, J1 = 16.50 Hz, J2 = 7.30 Hz, C3,
THPO), 3.73 (s, 3H, OCH3), 4.29 (d, 1H, J = 1.90 Hz, C3',
b-lactam), 4.61 (t, 1H, J1,2 = 6.60 Hz, C2, THPO), 4.68 (bs,
1H, C4', b-lactam), 5.25 (d, 1H, J = 7.90 Hz, C5, THPO),
6.72-6.76 (m, 2H, C3 and C5, PMP and 1H, C6, THPO),
7.10-7.35 (m, 2H, C2 and C6, PMP and 10H, Ph); 13C NMR
(CDCl3) d/ppm: 43.60 (C3, THPO), 55.42 (OCH3), 64.21
(C2, THPO), 65.01 (C4', b-lactam), 76.94 (C3', b-lactam),
101.44 (C5, THPO), 114.42 (C3 and C5, PMP), 119.02 (C2
and C6, PMP), 125.78 (C4, Ph), 127.02 (C4, Ph, b-lactam),
128.74 (C2 and C6, Ph, b-lactam), 128.80 (C2 and C6, Ph),
129.01 (C3 and C5, Ph, b-lactam), 129.25 (C3 and C5, Ph),
129.85 (C1, PMP), 134.97 (C1, Ph), 139.40 (C1, Ph,
b-lactam), 148.62 (C6, THPO), 156.74 (C4, PMP), 161.82
(CO, b-lactam), 190.46 (C4, THPO).
(2S)-1-[trans-(3'R,4'R)-1'-(4-Methoxyphenyl)-2'-oxo-4'-
phenylazetidin-3'-yl]-2-phenyl-1,2,3,4-tetrahydropyridin-4-one
(4a). – 35.1 mg; IR (KBr) nmax/cm–1: 3449, 1752, 1654,
1648, 1594, 1512, 1249, 830, 699; 1H NMR (CDCl3) d/ppm:
2.79 (dd, 1H, J1 = 16.40 Hz, J2 = 8.40 Hz, C3, THPO), 2.95
(dd, 1H, J1 = 16.40 Hz, J2 = 6.50 Hz, C3, THPO), 3.73 (s,
3H, OCH3), 4.29 (d, 1H, J = 2.20 Hz, C3', b-lactam), 4.65 (t,
1H, J1,2 = 6.60 Hz, C2, THPO), 4.69 (d, 1H, J = 2.10 Hz,
C4', b-lactam), 5.24 (d, 1H, J = 7.90 Hz, C5, THPO),
6.72–6.76 (m, 2H, C3 and C5, PMP and 1H, C6, THPO),
7.10–7.35 (m, 2H, C2 and C6, PMP and 10H, Ph); 13C NMR
(CDCl3) d/ppm: 43.59 (C3, THPO), 55.37 (OCH3), 62.81
(C2, THPO), 64.95 (C4', b-lactam), 76.87 (C3', b-lactam),
102.43 (C5, THPO), 114.40 (C3 and C5, PMP), 118.98 (C2
and C6, PMP), 128.69 (C4, Ph), 128.76 (C4, Ph, b-lactam),
128.96 (C2 and C6, Ph, b-lactam), 129.09 (C2 and C6, Ph),
129.20 (C3 and C5, Ph, b-lactam), 129.34 (C3 and C5, Ph),
129.79 (C1, PMP), 135.41 (C1, Ph), 139.34 (C1, Ph,
b-lactam), 149.97 (C6, THPO), 156.68 (C4, PMP), 161.77
(CO, b-lactam), 190.54 (C4, THPO).
(2R/2S)-2-(4-Methoxyphenyl)-1-[trans-(3'R,4'R)-1'-
(4-methoxyphenyl)-2'-oxo-4'-phenylazetidin-3'-yl]-1,2,3,4-
tetrahydropyridin-4-one (3b/4b). – Obtained from (3R,4R)-
1b (50.0 mg, 1.29 × 10–1 mmol), diene 2a (27.6 mg, 1.42 ×
10–1 mmol) and zinc(II) iodide (8.3 mg, 2.59 × 10–2 mmol)
as a diastereomeric mixture 3b/4b, 45.2 mg (77 %), Rf =
0.32 (eluens-A). RP-HPLC analysis of diastereomeric mix-
ture showed ratio of 3b/4b – 66:34 % (3b, 24.34 min and
4b, 24.74 min). LC-MS for C28H26N2O4 (Mr = 454.5283):
calcd. m/z [M+H]+ 455.53, found 455.20 (3b, 10.48 min) and
455.20 (4b, 10.89 min). IR (KBr) nmax/cm–1: 3467, 2918,
1750, 1591, 1513, 1457, 1300, 1249, 1179, 831; 1H NMR
(CDCl3) d/ppm: 2.68 (dd, 1H, J1 = 16.50 Hz, J2 = 7.20 Hz,
C3, THPO, 3b), 2.80 (dd, 1H, J1 = 16.44 Hz, J2 = 9.36 Hz,
C3, THPO, 4b), 2.87 (dd, 1H, J1 = 16.44 Hz, J2 = 6.18 Hz,
C3, THPO, 4b), 2.98 (dd, 1H, J1 = 16.50 Hz, J2 = 7.02 Hz,
C3, THPO, 3b), 3.72 (s, 3H, OCH3, PMP, THPO, 3b), 3.73 (s,
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3H, OCH3, PMP, THPO, 4b), 3.74 (s, 3H, OCH3, PMP, 3b),
3.73 (s, 3H, OCH3, PMP, 4b), 4.27 (d, 1H, J = 1.92 Hz, C3',
b-lactam, 3b), 4.29 (d, 1H, J = 1.86 Hz, C3', b-lactam, 4b),
4.56–4.62 (m, 2 × 1H, C2, THPO, 3b/4b), 4.64 (d, 1H, J =
1.44 Hz, C4', b-lactam, 3b), 4.68 (d, 1H, J = 1.80 Hz, C4',
b-lactam, 4b), 5.24 (d, 2 × 1H, J = 7.92 Hz, C5, THPO,
3b/4b), 6.64 (d, 2H, J = 8.58 Hz, C3 and C5, PMP, THPO,
3b), 6.71 (d, 2H, J = 8.58 Hz, C3 and C5, PMP, THPO, 4b),
6.74 (d, 2H, J = 9.06 Hz, C3 and C5, PMP, b-lactam, 3b),
6.76 (d, 2H, J = 9.18 Hz, C3 and C5, PMP, b-lactam, 4b),
6.83 (d, 2 ´ 1H, J = 7.14 Hz, C6, THPO, 3b/4b), 7.07 (d, 2H,
J = 8.58 Hz, C2 and C6, PMP, THPO, 4b), 7.11 (d, 2H, J =
8.58 Hz, C2 and C6, PMP, THPO, 3b), 7.15 (d, 2 ´ 2H, J =
8.82 Hz, C2 and C6, PMP, b-lactam, 3b/4b), 7.18-7.35 (m, 2
´ 5H, Ph, 3b/4b); 13C NMR (CDCl3) d/ppm: 43.68 (C3,
THPO, 3b), 43.78 (C3, THPO, 4b), 55.21 (2 ´ OCH3, 3b/4b),
55.38 (2 ´ OCH3, 3b/4b), 61.23 (C2, THPO, 4b), 62.92 (C4',
b-lactam, 4b), 63.60 (C2, THPO, 3b), 65.09 (C4', b-lactam,
3b), 76.18 (C3', b-lactam, 4b), 76.54 (C3', b-lactam, 3b),
101.25 (C5, THPO, 3b), 102.42 (C5, THPO, 4b), 114.35 (C3
and C5, PMP, 3b), 114.37 (C3 and C5, PMP, 4b), 114.46 (2 ´
C3 and 2 ´ C5, PMP, 3b/4b), 118.95 (2 ´ C2 and 2 ´ C6,
PMP, b-lactam, 3b/4b), 125.78 (C2 and C6, PMP, THPO, 4b),
125.88 (C2 and C6, PMP, THPO, 3b), 128.32 (C2 and C6, Ph,
4b), 128.36 (C2 and C6, Ph, 3b), 128.77 (C3 and C5, Ph, 4b),
128.92 (C3 and C5, Ph, 3b), 129.05 (C4, Ph, 4b), 129.34 (C4,
Ph, 3b), 129.53 (C1, PMP, THPO, 4b), 129.81 (C1, PMP,
THPO, 3b), 131.13 (2 ´ C1, PMP, b-lactam, 3b/4b), 134.99
(2 ´ C1, Ph, 3b/4b), 148.69 (C6, THPO, 3b), 149.94 (C6,
THPO, 4b), 156.65 (2 ´ C4, PMP, b-lactam, 3b/4b), 159.84
(2 ´ C4, PMP, THPO, 3b/4b), 162.00 (2 ´ CO, b-lactam,
3b/4b), 190.86 (C4, THPO, 3b), 191.01 (C4, THPO, 4b).
(2R/2S)-2-(3,4-Dimethoxyphenyl)-1-[trans-(3'R,4'R)-1'-
(4-methoxyphenyl)-2'-oxo-4'-phenylazetidin-3'-yl]-1,2,3,4-
tetrahydropyridin-4-one (3c/4c). – Obtained from (3R,4R)-1c
(50.0 mg, 1.20 × 10–1 mmol), diene 2a (25.8 mg, 1.32 × 10–1
mmol) and zinc(II) iodide (6.4 mg, 2.40 × 10–2 mmol) as a
diastereomeric mixture 3c/4c, 53.4 mg (92 %), Rf = 0.37
(eluens-C). RP-HPLC analysis of diastereomeric mixture
showed ratio of 3c/4c – 70:30 % (3c, 23.19 min and 4c,
23.77 min). LC-MS for C29H28N2O5 (Mr = 484.5547): calcd.
m/z [M+H]+ 485.55, found 485.20 (3c, 9.53 min) and 485.20
(4c, 10.04 min). Diastereomeric mixture of 3c/4c was sepa-
rated by a silica gel column chromatography using eluens-C.
(2R)-2-(3,4-Dimethoxyphenyl)-1-[trans-(3'R,4'R)-1'-
(4-methoxyphenyl)-2'-oxo-4'-phenylazetidin-3'-yl]-1,2,3,4-
tetrahydropyridin-4-one (3c). – 37.4 mg; IR (KBr) nmax/cm-1:
3448, 2934, 2837, 1750, 1589, 1513, 1249, 1141, 831; 1H NMR
(CDCl3) d/ppm: 2.72 (dd, 1H, J1 = 16.54 Hz, J2 = 7.14 Hz,
C3, THPO), 3.02 (dd, 1H, J1 = 16.51 Hz, J2 = 7.11 Hz, C3,
THPO), 3.68 (s, 3H, OCH3), 3.72 (s, 3H, OCH3), 3.82 (s,
3H, OCH3), 4.33 (d, 1H, J = 2.10 Hz, C3', b-lactam), 4.55 (t,
1H, J1,2 = 7.08 Hz, C2, THPO), 4.62 (d, 1H, J = 2.04 Hz,
C4', b-lactam), 5.26 (d, 1H, J = 7.92 Hz, C5, THPO), 6.57
(d, 1H, J = 8.25 Hz, 3,4-(CH3O)2-Ph), 6.66 (d, 1H, J = 1.95
Hz, C6, THPO), 6.74 (d, 2H, J = 9.06 Hz, C3 and C5, PMP),
6.77-6.85 (m, 2H, 3,4-(CH3O)2-Ph), 7.14 (d, 2H, J = 9.03
Hz, C2 and C6, PMP), 7.20-7.30 (m, 5H, Ph); 13C NMR
(CDCl3) d/ppm: 43.49 (C3, THPO), 55.38 (OCH3), 55.71,
55.83 (2 ´ OCH3, 3,4-(CH3O)2-Ph), 64.05 (C2, THPO),
64.99 (C4', b-lactam), 76.50 (C3', b-lactam), 101.19 (C5,
THPO), 110.02 (C6, 3,4-(CH3O)2-Ph), 111.40 (C5,
3,4-(CH3O)2-Ph), 114.34 (C3 and C5, PMP), 118.93 (C2 and
C6, PMP), 119.58 (C2, 3,4-(CH3O)2-Ph), 125.83 (C4, Ph),
128.85 (C2 and C6, Ph), 128.92 (C3 and C5, Ph), 129.77
(C1, PMP), 131.69 (C1, 3,4-(CH3O)2-Ph), 134.94 (C1, Ph),
148.78 (C6, THPO), 149.25 (C4, 3,4-(CH3O)2-Ph), 149.33
(C3, 3,4-(CH3O)2-Ph), 156.66 (C4, PMP), 162.02 (CO,
b-lactam), 191.05 (C4, THPO).
(2S)-2-(3,4-Dimethoxyphenyl)-1-[trans-(3'R,4'R)-1'-
(4-methoxyphenyl)-2'-oxo-4'-phenylazetidin-3'-yl]-1,2,3,4-
tetrahydropyridin-4-one (4c). – 16.0 mg; IR (KBr) nmax/cm-1:
3448, 2934, 2837, 1750, 1589, 1513, 1249, 1141, 831; 1H NMR
(CDCl3) d/ppm: 2.80 (dd, 1H, J1 = 16.39 Hz, J2 = 9.12 Hz,
C3, THPO), 2.89 (dd, 1H, J1 = 16.54 Hz, J2 = 6.66 Hz, C3,
THPO), 3.70 (s, 3H, OCH3), 3.73 (s, 3H, OCH3), 3.82 (s, 3H,
OCH3), 4.30 (d, 1H, J = 2.22 Hz, C3', b-lactam), 4.58 (dd,
1H, J1 = 8.97 Hz, J2 = 6.48 Hz, C2, THPO), 4.69 (d, 1H, J =
2.13 Hz, C4', b-lactam), 5.25 (d, 1H, J = 7.86 Hz, C5, THPO),
6.64-6.72 (m, 3H, 3,4-(CH3O)2-Ph and 1H, C6, THPO), 6.77
(d, 2H, J = 9.09 Hz, C3 and C5, PMP), 7.16 (d, 2H, J = 9.03
Hz, C2 and C6, PMP), 7.20-7.30 (m, 5H, Ph); 13C NMR
(CDCl3) d/ppm: 43.85 (C3, THPO), 55.41 (OCH3), 55.77,
55.90 (2 ´ OCH3, 3,4-(CH3O)2-Ph), 61.73 (C2, THPO),
63.05 (C4', b-lactam), 76.04 (C3', b-lactam), 102.48 (C5,
THPO), 109.63 (C6, 3,4-(CH3O)2-Ph), 111.33 (C5,
3,4-(CH3O)2-Ph), 114.40 (C3 and C5, PMP), 118.95 (C2
and C6, PMP), 119.58 (C2, 3,4-(CH3O)2-Ph), 125.82 (C4,
Ph), 129.09 (C2 and C6, Ph), 129.39 (C3 and C5, Ph),
129.75 (C1, PMP), 130.14 (C1, 3,4-(CH3O)2-Ph), 135.56
(C1, Ph), 147.17 (C4, 3,4-(CH3O)2-Ph), 149.17 (C3,
3,4-(CH3O)2-Ph), 149.87 (C6, THPO), 156.69 (C4, PMP),
161.70 (CO, b-lactam), 191.05 (C4, THPO).
(2R/2S)-2-(4-Fluorophenyl)-1-[trans-(3'R,4'R)-1'-
(4-methoxyphenyl)-2'-oxo-4'-phenylazetidin-3'-yl]-1,2,3,4-
tetrahydropyridin-4-one (3d/4d). – Obtained from (3R,4R)-1d
(40.0 mg, 1.07 × 10–1 mmol), diene 2a (22.4 mg, 1.18 × 10–1
mmol) and zinc(II) iodide (7.0 mg, 2.14 × 10–2 mmol) as a
diastereomeric mixture 3d/4d, 38.5 mg (81 %), Rf = 0.30
(eluens-A). RP-HPLC analysis of diastereomeric mixture
showed ratio of 3d/4d – 70:30 % (3d, 24.32 min and 4d,
24.76 min). LC-MS for C27H23FN2O3 (Mr = 442.4924):
calcd. m/z [M+H]+ 443.49, found 443.20 (3d, 10.57 min)
and 443.20 (4d, 11.02 min). IR (KBr) nmax/cm-1: 3448,
2927, 1751, 1589, 1513, 1300, 1249, 831; 1H NMR (CDCl3)
d/ppm: 2.65 (dd, 1H, J1 = 16.48 Hz, J2 = 6.42 Hz, C3,
THPO, 3d), 2.76 (dd, 1H, J1 = 16.40 Hz, J2 = 8.49 Hz, C3,
THPO, 4d), 2.93 (dd, 1H, J1 = 16.45 Hz, J2 = 6.39 Hz, C3,
THPO, 4d), 3.04 (dd, 1H, J1 = 16.51 Hz, J2 = 7.26 Hz, C3,
THPO, 3d), 3.72 (s, 3H, OCH3, 3d), 3.73 (s, 3H, OCH3, 4d),
4.26 (d, 1H, J = 2.16 Hz, C4', b-lactam, 4d), 4.29 (d, 1H, J =
2.10 Hz, C4', b-lactam, 3d), 4.61 (bs, 1H, C2, THPO, 4d),
4.63 (bs, 1H, C2, THPO, 3d), 4.65 (d, 1H, J = 1.92 Hz, C3',
b-lactam, 3d), 4.70 (d, 1H, J = 2.16 Hz, C3', b-lactam, 4d),
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5.25 (d, 2 ´ 1H, J = 7.92 Hz, C5, THPO, 3d/4d), 6.72-6.96
(m, 2 ´ 2H, C3 and C5, PMP, 2 ´ 1H, C6, THPO and 2 ´
2H, C3 and C5, 4-F-Ph, 3d/4d), 7.12-7.38 (m, 2 ´ 2H, C2
and C6, PMP, 2 ´ 2H, C2 and C6, 4-F-Ph and 2 ´ 5H, Ph,
3d/4d); 13C NMR (CDCl3) d/ppm: 43.41 (C3, THPO, 3d),
43.63 (C3, THPO, 4d), 55.38 (2 ´ OCH3, 3d/4d), 60.95 (C2,
THPO, 4d), 62.94 (C4', b-lactam, 4d), 63.25 (C2, THPO,
3d), 64.99 (C4', b-lactam, 3d), 76.32 (C3', b-lactam, 4d),
76.81 (C3', b-lactam, 3d), 101.40 (C5, THPO, 3d), 102.63
(C5, THPO, 4d), 114.38 (2 ´ C3 and 2 ´ C5, PMP, 3d/4d),
116.11 (d, J = 18.58 Hz, 2 ´ C3 and 2 ´ C5, 4-F-Ph, 3d/4d),
118.96 (2 ´ C2 and 2 ´ C6, PMP, 3d/4d), 125.73 (2 ´ C2
and 2 ´ C6, Ph, 3d/4d), 128.80 (d, J = 8.00 Hz, 2 ´ C2 and 2
´ C6, 4-F-Ph, 3d/4d), 129.01 (2 ´ C4, Ph, 3d/4d), 129.08 (2
´ C3 and 2 ´ C5, Ph, 3d/4d), 129.62 (2 ´ C1, PMP, 3d/4d),
134.81 (2 ´ C1, Ph, 3d/4d), 135.12 (d, J = 3.27 Hz, 2 ´ C1,
4-F-Ph, 3d/4d), 148.66 (C6, THPO, 3d), 149.86 (C6, THPO,
4d), 156.73 (2 ´ C4, PMP, 3d/4d), 161.39 (CO, b-lactam,
4d), 161.67 (CO, b-lactam, 3d), 164.41 (2 ´ C4, 4-F-Ph,
3d/4d), 190.43 (C4, THPO, 3d), 190.51 (C4, THPO, 4d).
(2R/2S)-2-(4-Trifluoromethylphenyl)-1-[trans-(3'R,4'R)-1'-
(4-methoxyphenyl)-2'-oxo-4'-phenylazetidin-3'-yl]-1,2,3,4-
tetrahydropyridin-4-one (3e/4e). – Obtained from (3R,4R)-1e
(30.0 mg, 7.07 × 10–2 mmol), diene 2a (13.8 mg, 7.78 × 10–2
mmol) and zinc(II) iodide (4.5 mg, 1.41 × 10–2 mmol) as a
diastereomeric mixture 3e/4e, 26.7 mg (77 %), Rf = 0.26
(eluens-A). RP-HPLC analysis of diastereomeric mixture
showed ratio of 3e/4e – 73:27 % (3e, 25.05 min and 4e,
25.36 min). LC-MS for C28H23F3N2O3 (Mr = 492.5003):
calcd. m/z [M+H]+ 493.50, found 493.20 (3e, 11.34 min) and
493.20 (4e, 11.68 min). IR (KBr) nmax/cm-1: 3449, 1752,
1654, 1648, 1594, 1512, 1249, 830, 699; 1H NMR (CDCl3)
d/ppm: 2.65 (dd, 1H, J1 = 16.51 Hz, J2 = 5.76 Hz, C3,
THPO, 3e), 2.75 (dd, 1H, J1 = 16.33 Hz, J2 = 7.47 Hz, C3,
THPO, 4e), 3.01 (dd, 1H, J1 = 16.39 Hz, J2 = 6.63 Hz, C3,
THPO, 4e), 3.11 (dd, 1H, J1 = 16.54 Hz, J2 = 7.53 Hz, C3,
THPO, 3e), 3.72 (s, 3H, OCH3, 3e), 3.73 (s, 3H, OCH3, 4e),
4.28 (d, 1H, J = 2,25 Hz, C4', b-lactam, 4e), 4.29 (d, 1H, J =
2.16 Hz, C4', b-lactam, 3e), 4.65 (d, 1H, J = 2.16 Hz, C3',
b-lactam, 3e), 4.66-4.75 (m, 2 ´ 1H, C2, THPO, 3e/4e and
1H, C3', b-lactam, 4e), 5.24 (d, 1H, J = 7.05 Hz, C5, THPO,
3e), 5.25 (d, 1H, J = 7.92 Hz, C5, THPO, 4e), 6.73-6.81 (m,
2 ´ 2H, C3 and C5, PMP and 2 ´ 1H, C6, THPO, 3e/4e),
7.12-7.54 (m, 2 ´ 2H, C2 and C6, PMP, 2 ´ 4H, C2, C3, C5
and C6, 4-CF3-Ph and 2 ´ 5H, Ph, 3e/4e); 13C NMR
(CDCl3) d/ppm: 42.91 (C3, THPO, 3e), 43.25 (C3, THPO,
4e), 55.37 (2 ´ OCH3, 3e/4e), 55.78 (d, J = 358.59 Hz, 2 ´
CF3, 3e/4e), 60.96 (C2, THPO, 4e), 62.99 (C4', b-lactam,
4e), 63.42 (C2, THPO, 3e), 64.97 (C4', b-lactam, 3e), 76.67
(C3', b-lactam, 4e), 77.12 (C3', b-lactam, 3e), 101.56 (C5,
THPO, 3e), 102.78 (C5, THPO, 4e), 114.37 (C3 and C5,
PMP, 3e), 114.42 (C3 and C5, PMP, 4e), 118.95 (2 ´ C2 and
2 ´ C6, PMP, 3e/4e), 125.59 (C2 and C6, Ph, 3e), 125.68
(C2 and C6, Ph, 4e), 126.10 (d, J = 3.83 Hz, C3 and C5,
4-CF3-Ph, 4e), 126.23 (d, J = 3.76 Hz, C3 and C5, 4-CF3-Ph,
3e), 127.23 (C3 and C5, Ph, 4e), 127.37 (C3 and C5, Ph, 3e),
129.12 (2 ´ C2 and 2 ´ C6, 4-CF3-Ph, 3e/4e), 129.30 (C4,
Ph, 4e), 129.49 (C4, Ph, 3e), 129.60 (2 ´ C1, PMP, 3e/4e),
134.64 (C1, 4-CF3-Ph, 3e), 135.14 (C1, 4-CF3-Ph, 4e), 143.38
(C4, 4-CF3-Ph, 3e), 143.40 (C4, 4-CF3-Ph, 4e), 148.56 (C6,
THPO, 3e), 149.72 (C6, THPO, 4e), 156.75 (C4, PMP, 3e),
156.78 (C4, PMP, 4e), 161.15 (CO, b-lactam, 4e), 161.33
(CO, b-lactam, 3e), 189.76 (C4, THPO, 4e), 189.79 (C4,
THPO, 3e).
(2R/2S)-1-[trans-(3'R,4'R)-1'-(4-Methoxyphenyl)-2'-oxo-4'-
phenylazetidin-3'-yl]-2-(2-nitrophenyl)-1,2,3,4-
tetrahydropyridin-4-one (3f/4f). – Obtained from (3R,4R)-
1f (15.0 mg, 3.74 × 10–2 mmol), diene 2b (10.7 mg, 4.11 ×
10–2 mmol) and zinc(II) iodide (2.6 mg, 7.47 × 10–3 mmol)
as a diastereomeric mixture 3f/4f, 10.31 mg (59 %), Rf =
0.19 (eluens-C). RP-HPLC analysis of diastereomeric mixture
showed ratio of 3f/4f – 73:27 % (3f, 25.60 min and 4f, 25.95
min). LC-MS for C27H23N3O5 (Mr = 469.4995): calcd. m/z
[M+H]+ 470.50, found 470.20 (3f, 10.52 min) and 470.20
(4f, 10.95 min). Diastereomeric mixture of 3f/4f was sepa-
rated by a silica gel column chromatography using eluens-C.
(2R)-1-[trans-(3'R,4'R)-1'-(4-Methoxyphenyl)-2'-oxo-4'-
phenylazetidin-3'-yl]-2-(2-nitrophenyl)-1,2,3,4-
tetrahydropyridin-4-one (3f). – 7.53 mg; IR (KBr) nmax/cm-1:
3449, 2926, 1752, 1636, 1594, 1513, 1458, 1300, 1249, 830;
1H NMR (CDCl3) d/ppm: 2.67 (dd, 1H, J1 = 16.81 Hz, J2 =
3.30 Hz, C3, THPO), 3.32 (dd, 1H, J1 = 16.81 Hz, J2 = 8.70
Hz, C3, THPO), 3.73 (s, 3H, OCH3), 4.41 (d, 1H, J = 2.10
Hz, C3', b-lactam), 4.73 (d, 1H, J = 2.10 Hz, C4', b-lactam),
5.24 (d, 1H, J = 7.80 Hz, C5, THPO), 5.42 (dd, 1H, J1 = 8.70
Hz, J2 = 3.30 Hz, C2, THPO), 6.75 (d, 2H, J = 9.00 Hz, C3
and C5, PMP), 6.82 (d, 1H, J = 6.60 Hz, C6, THPO), 7.14
(d, 2H, J = 8.70 Hz, C2 and C6, PMP), 7.20-7.30 (m, 5H,
Ph), 7.37 (d, 1H, J = 7.80 Hz, C6, Ph-NO2), 7.48 (t, 1H, J1,2
= 8.10 Hz, C4, Ph-NO2), 7.60 (t, 1H, J1,2 = 7.80 Hz, C5,
Ph-NO2), 7.88 (dd, 1H, J1 = 20.11 Hz, J2 = 7.80 Hz, C3,
Ph-NO2); 13C NMR (CDCl3) d/ppm: 42.66 (C3, THPO),
55.38 (OCH3), 62.55 (C2, THPO), 64.70 (C4', b-lactam),
77.16 (C3', b-lactam), 101.90 (C5, THPO), 114.38 (C3 and
C5, PMP), 118.92 (C2 and C6, PMP), 124.38 (C3, Ph-NO2),
125.70 (C2 and C6, Ph), 127.91 (C6, Ph-NO2), 129.23 (C3
and C5, Ph), 129.48 (C1, PMP), 129.60 (C4, Ph), 131.38
(C4, Ph-NO2), 133.49 (C5, Ph-NO2), 134.56 (C1, Ph),
146.09 (C1, Ph-NO2), 147.89 (C2, Ph-NO2), 148.75 (C6,
THPO), 156.78 (C4, PMP), 161.03 (CO, b-lactam), 189.39
(C4, THPO).
(2S)-1-[trans-(3'R,4'R)-1'-(4-Methoxyphenyl)-2'-oxo-4'-
phenylazetidin-3'-yl]-2-(2-nitrophenyl)-1,2,3,4-
tetrahydropyridin-4-one (4f). – 2.78 mg; IR (KBr) nmax/cm-1:
3449, 2926, 1752, 1636, 1594, 1513, 1458, 1300, 1249,
830; 1H NMR (CDCl3) d/ppm: 2.68 (dd, 1H, J1 = 16.81 Hz,
J2 = 5.70 Hz, C3, THPO), 3.26 (dd, 1H, J1 = 16.81 Hz, J2 =
7.80 Hz, C3, THPO), 3.74 (s, 3H, OCH3), 4.17 (d, 1H, J =
2.10 Hz, C3', b-lactam), 4.83 (d, 1H, J = 1.80 Hz, C4',
b-lactam), 5.28 (d, 1H, J = 8.10 Hz, C5, THPO), 5.51 (m,
1H, C2, THPO), 6.75 (d, 2H, J = 9.00 Hz, C3 and C5,
PMP), 6.83 (m, 1H, C6, THPO), 7.10-7.30 (m, 2H, C2 and
C6, PMP and 5H, Ph), 7.34 (m, 1H, C6, Ph-NO2), 7.46 (m,
1H, C4, Ph-NO2), 7.67 (t, 1H, J1,2 = 7.80 Hz, C5, Ph-NO2),
7.88 (dd, 1H, J1 = 23.71 Hz, J2 = 8.10 Hz, C3, Ph-NO2);
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13C NMR (CDCl3) d/ppm: 43.02 (C3, THPO), 55.38 (OCH3),
60.64 (C2, THPO), 63.06 (C4', b-lactam), 76.87 (C3',
b-lactam), 103.02 (C5, THPO), 114.44 (C3 and C5, PMP),
118.92 (C2 and C6, PMP), 124.38 (C3, Ph-NO2), 125.63 (C2
and C6, Ph), 127.72 (C6, Ph-NO2), 129.35 (C3 and C5, Ph),
129.48 (C1, PMP), 129.60 (C4, Ph), 131.38 (C4, Ph-NO2),
133.49 (C5, Ph-NO2), 134.99 (C1, Ph), 144.89 (C1, Ph-NO2),
148.05 (C2, Ph-NO2), 149.57 (C6, THPO), 156.78 (C4,
PMP), 160.95 (CO, b-lactam), 189.36 (C4, THPO).
(2R/2S)-1-[trans-(3'R,4'R)-1'-(4-Methoxyphenyl)-2'-oxo-4'-
phenylazetidin-3'-yl]-2-(3-nitrophenyl)-1,2,3,4-
tetrahydropyridin-4-one (3g/4g). – Obtained from (3R,4R)-
1g (15.0 mg, 3.74 × 10–2 mmol), diene 2b (10.7 mg, 4.11 ×
10–2 mmol) and zinc(II) iodide (2.6 mg, 7.47 × 10–3 mmol)
as a diastereomeric mixture 3g/4g, 14.89 mg (85 %), Rf =
0.12 (eluens-A). RP-HPLC analysis of diastereomeric mix-
ture showed ratio of 3g/4g – 73:27 % (3g, 25.70 min and 4g,
26.05 min). LC-MS for C27H23N3O5 (Mr = 469.4995): calcd.
m/z [M+H]+ 470.50, found 470.20 (3g, 10.52 min) and
470.20 (4g, 10.86 min). IR (KBr) nmax/cm-1: 3448, 1751,
1647, 1593, 1530, 1513, 1457, 1349, 1249, 831, 700; 1H
NMR (CDCl3) d/ppm: 2.70 (dd, 1H, J1 = 16.51 Hz, J2 = 5.70
Hz, C3, THPO, 3g), 2.77 (m, 1H, C3, THPO, 4g), 3.00-3.18
(m, 2 ´ 1H, C3, THPO, 3g/4g), 3.72 (s, 3H, OCH3, 3g), 3.73
(s, 3H, OCH3, 4g), 4.27 (d, 1H, J = 1.80 Hz, C3', b-lactam,
4g), 4.32 (d, 1H, J = 1.50 Hz, C3', b-lactam, 3g), 4.72 (d,
1H, J = 1.80 Hz, C4', b-lactam, 3g), 4.75-4.85 (m, 1H, C4',
b-lactam, 4g and 2 ´ 1H, C2, THPO, 3g/4g), 5.28 (d, 1H, J =
7.80 Hz, C5, THPO, 4g), 5.29 (d, 1H, J = 8.10 Hz, C5,
THPO, 3g), 6.70-6.80 (m, 2 ´ 2H, C3 and C5, PMP, 3g/4g),
6.89 (d, 2 ´ 1H, J = 7.20 Hz, C6, THPO, 3g/4g), 7.10-7.55
(m, 2 ´ 2H, C2 and C6, PMP and 2 ´ 5H, Ph, 3g/4g),
7.60-7.70 (m, 2 ´ 1H, C5, Ph-NO2, 3g/4g), 8.00-8.15 (m, 2 ´
2H, C4 and C6, Ph-NO2, 3g/4g); 13C NMR (CDCl3) d/ppm:
43.01 (C3, THPO, 3g), 43.22 (C3, THPO, 4g), 55.39 (2 ´
OCH3, 3g/4g), 60.70 (C2, THPO, 4g), 62.71 (C2, THPO,
3g), 62.97 (C4', b-lactam, 4g), 64.75 (C4', b-lactam, 3g),
76.80 (C3', b-lactam, 4g), 77.17 (C3', b-lactam, 3g), 102.09
(C5, THPO, 3g), 103.26 (C5, THPO, 4g), 114.40 (C3 and
C5, PMP, 3g), 114.45 (C3 and C5, PMP, 4g), 118.92 (C2 and
C6, PMP, 4g), 118.95 (C2 and C6, PMP, 3g), 121.89 (C4,
Ph-NO2, 3g), 122.03 (C4, Ph-NO2, 4g), 123.65 (2 ´ C2,
Ph-NO2, 3g/4g), 125.56 (2 ´ C2 and 2 ´ C6, Ph, 3g/4g),
129.21 (C3 and C5, Ph, 3g), 129.29 (C3 and C5, Ph, 4g),
129.43 (C5, Ph-NO2, 4g), 129.54 (2 ´ C1, PMP, 3g/4g),
129.61 (C5, Ph-NO2, 3g), 130.40 (2 ´ C4, Ph, 3g/4g), 132.63
(C6, Ph-NO2, 4g), 133.08 (C6, Ph-NO2, 3g), 134.55 (C1, Ph,
3g), 134.95 (C1, Ph, 4g), 139.69 (C1, Ph-NO2, 4g), 141.22
(C1, Ph-NO2, 3g), 148.35 (2 ´ C3, Ph-NO2, 3g/4g), 148.68
(C6, THPO, 3g), 149.54 (C6, THPO, 4g), 156.80 (C4, PMP,
3g), 156.82 (C4, PMP, 4g), 160.94 (CO, b-lactam, 4g),
161.15 (CO, b-lactam, 3g), 189.33 (C4, THPO, 4g), 189.36
(C4, THPO, 3g).
(2R/2S)-1-[trans-(3'R,4'R)-1'-(4-Methoxyphenyl)-2'-oxo-4'-
phenylazetidin-3'-yl]-2-(4-nitrophenyl)-1,2,3,4-
tetrahydropyridin-4-one (3h/4h). – Obtained from (3R,4R)-1h
(15.0 mg, 3.74 × 10–2 mmol), diene 2b (10.7 mg, 4.11 × 10–2
mmol) and zinc(II) iodide (2.6 mg, 7.47 × 10–3 mmol) as a
diastereomeric mixture 3h/4h, 17.1 mg (97 %), Rf = 0.11
(eluens-A). RP-HPLC analysis of diastereomeric mixture
showed ratio of 3h/4h – 78:22 % (3h, 25.70 min and 4h,
25.95 min). LC-MS for C27H23N3O5 (Mr = 469.4995): calcd.
m/z [M+H]+ 470.50, found 470.20 (3h, 10.50 min) and
470.20 (4h, 10.85 min). IR (KBr) nmax/cm-1: 3449, 2925,
1750, 1647, 1588, 1512, 1346, 1248, 830, 698; 1H NMR
(CDCl3) d/ppm: 2.62-2.78 (m, 2 ´ 1H, C3, THPO, 3h/4h),
3.02-3.08 (m, 1H, C3, THPO, 4h), 3.14 (dd, 1H, J1 = 16.51
Hz, J2 = 7.50 Hz, C3, THPO, 3h), 3.72 (s, 3H, OCH3, 3h),
3.74 (s, 3H, OCH3, 4h), 4.28 (d, 1H, J = 2.10 Hz, C3',
b-lactam, 4h), 4.33 (d, 1H, J = 2.10 Hz, C3', b-lactam, 3h),
4.70 (d, 1H, J = 2.10 Hz, C4', b-lactam, 3h), 4.76 (d, 1H, J =
2.10 Hz, C4', b-lactam, 4h), 4.78-4.85 (m, 2 ´ 1H, C2,
THPO, 3h/4h), 5.27 (d, 1H, J = 7.80 Hz, C5, THPO, 4h),
5.28 (d, 1H, J = 8.10 Hz, C5, THPO, 3h), 6.75 (d, 2 ´ 2H, J
= 9.00 Hz, C3 and C5, Ph, 3h/4h), 6.90 (d, 2 ´ 1H, J = 6.90
Hz, C6, THPO, 3h/4h), 7.14 (d, 2 ´ 2H, J = 9.00 Hz, C2 and
C6, Ph, 3h/4h), 7.15-7.40 (m, 2 ´ 5H, Ph, 3h/4h), 7.43 (d, 2
´ 2H, J = 8.70 Hz, C2 and C6, Ph-NO2, 3h/4h), 8.02 (d, 2H,
J = 8.70 Hz, C3 and C5, Ph-NO2, 3h), 8.14 (d, 2H, J = 8.70
Hz, C2 and C6, Ph-NO2, 4h); 13C NMR (CDCl3) d/ppm:
42.65 (C3, THPO, 3h), 44.87 (C3, THPO, 4h), 55.37 (2 ´
OCH3, 3h/4h), 60.64 (C2, THPO, 4h), 62.54 (C2, THPO,
3h), 63.05 (C4', b-lactam, 4h), 64.69 (C4', b-lactam, 3h),
76.86 (C3', b-lactam, 4h), 77.15 (C3', b-lactam, 3h), 101.89
(C5, THPO, 3h), 103.01 (C5, THPO, 4h), 114.37 (C3 and
C5, PMP, 3h), 114.43 (C3 and C5, PMP, 4h), 118.91 (2 ´ C2
and 2 ´ C6, PMP, 3h/4h), 124.37 (2 ´ C3 and 2 ´ C5,
Ph-NO2, 3h/4h), 125.62 (C2 and C6, Ph, 4h), 125.69 (C2
and C6, Ph, 3h), 127.71 (C2 and C6, Ph-NO2, 4h), 127.90
(C2 and C6, Ph-NO2, 3h), 129.22 (C3 and C5, Ph, 3h),
129.35 (C3 and C5, Ph, 4h), 129.47 (2 ´ C1, PMP, 3h/4h),
129.59 (2 ´ C4, Ph, 3h/4h), 134.53 (C1, Ph, 4h), 134.55
(C1, Ph, 3h), 144.88 (2 ´ C1, Ph-NO2, 3h/4h), 146.08 (C4,
Ph-NO2, 3h), 147.88 (C4, Ph-NO2, 4h), 148.74 (C6, THPO,
3h), 149.54 (C6, THPO, 4h), 156.77 (2 ´ C4, PMP, 3h/4h),
160.94 (CO, b-lactam, 4h), 161.02 (CO, b-lactam, 3h),
189.34 (C4, THPO, 4h), 189.38 (C4, THPO, 3h).
(2R/2S)-2-Cyclohexyl-1-[trans-(3'R,4'R)-1'-
(4-methoxyphenyl)-2'-oxo-4'-phenylazetidin-3'-yl]-1,2,3,4-
tetrahydropyridin-4-one (3i/4i). – Obtained from (3R,4R)-1i
(30.0 mg, 8.28 × 10–2 mmol), diene 2a (17.1 mg, 9.11 × 10–2
mmol) and zinc(II) iodide (5.3 mg, 1.66 × 10–2 mmol) as a
diastereomeric mixture 3i/4i, 14.02 mg (39 %), Rf = 0.30
(eluens-A). RP-HPLC analysis of diastereomeric mixture
showed ratio of 3i/4i – 60:40 % (3i, 25.17 min and 4i, 25.78
min). LC-MS for C27H30N2O3 (Mr = 430.5496): calcd. m/z
[M+H]+ 431.55, found 431.20 (3i, 11.39 min) and 431.20
(4i, 12.04 min). IR (KBr) nmax/cm-1: 3468, 2926, 2851,
1751, 1645, 1591, 1513, 1386, 1300, 1248, 830; 1H NMR
(CDCl3) d/ppm: 1.00-1.30 (m, 2 ´ 6H, cyclohexyl, 3i/4i),
1.55-1.80 (m, 2 ´ 5H, cyclohexyl, 3i/4i), 2.45-2.55 (m, 2 ´
1H, C2, THPO, 3i/4i), 3.75 (s, 3H, OCH3, 3i), 3.76 (s, 3H,
OCH3, 4i), 4.32 (d, 1H, J = 2.04 Hz, C4', b-lactam, 3i), 4.39
(d, 1H, J = 2.10 Hz, C4', b-lactam, 4i), 4.84 (d, 1H, J = 1.95
Hz, C3', b-lactam, 4i), 4.87 (d, 1H, J = 1.98 Hz, C3',
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b-lactam, 3i), 5.03 (d, 1H, J = 7.80 Hz, C5, THPO, 3i), 5.10
(d, 1H, J = 7.59 Hz, C5, THPO, 4i), 6.79 (d, 2H, J = 9.03
Hz, C3 and C5, PMP, 3i), 6.78-6.82 (m, 2H, C3 and C5,
PMP, 4i), 7.09 (d, 2 ´ 1H, J = 7.83 Hz, C6, THPO, 3i/4i),
7.19 (m, 2H, C2 and C6, PMP, 4i), 7.24 (d, 2H, J = 9.09 Hz,
C2 and C6, PMP, 3i), 7.30-7.44 (m, 2 ´ 5H, Ph, 3i/4i); 13C
NMR (CDCl3) d/ppm: 26.07 (C2 and C6, cyclohexyl, 4i),
26.10 (C2 and C6, cyclohexyl, 3i), 27.85 (C3 and C5,
cyclohexyl, 3i), 28.45 (C3 and C5, cyclohexyl, 4i), 29.25
(C4, cyclohexyl, 3i), 29.83 (C4, cyclohexyl, 4i), 36.68 (C3,
THPO, 3i), 37.70 (C3, THPO, 4i), 38.95 (C1, cyclohexyl,
4i), 41.92 (C1, cyclohexyl, 3i), 55.41 (2 ´ OCH3, 3i/4i),
63.67 (C2, THPO, 4i), 64.58 (C2, THPO, 3i), 65.32 (C4',
b-lactam, 4i), 65.37 (C4', b-lactam, 3i), 77.86 (C3', b-lactam,
4i), 78.40 (C3', b-lactam, 3i), 100.22 (C5, THPO, 3i), 101.37
(C5, THPO, 4i), 114.43 (C3 and C5, PMP, 3i), 114.46 (C3
and C5, PMP, 4i), 119.00 (C2 and C6, PMP, 4i), 119.06 (C2
and C6, PMP, 3i), 125.57 (C2 and C6, Ph, 4i), 126.20 (C2
and C6, Ph, 3i), 129.23 (C4, Ph, 4i), 129.43 (C3 and C5, Ph,
4i), 129.48 (C3 and C5, Ph, 3i), 129.61 (C4, Ph, 3i), 129.76
(2 ´ C1, PMP, 3i/4i), 135.22 (2 ´ C1, Ph, 3i/4i), 147.91 (C6,
THPO, 4i), 148.02 (C6, THPO, 3i), 156.73 (2 ´ C4, PMP,
3i/4i), 162.04 (2 ´ CO, b-lactam, 3i/4i), 191.52 (C4, THPO,
3i), 191.64 (C4, THPO, 4i).
(2R/2S)-2-tert-Butyl-1-[trans-(3'R,4'R)-1'-(4-methoxyphenyl)
-2'-oxo-4'-phenylazetidin-3'-yl]-1,2,3,4-tetrahydropyridin-4-
one (3j/4j). – Obtained from (3R,4R)-1j (18.0 mg, 5.35 × 10–2
mmol), diene 2a (12.1 mg, 5.89 × 10–2 mmol) and zinc(II)
iodide (3.4 mg, 1.07 × 10–2 mmol) as a diastereomeric mix-
ture 3j/4j, 9.6 mg (44 %), Rf = 0.37 (eluens-A). RP-HPLC
analysis of diastereomeric mixture showed ratio of 3j/4j –
55:45 % (3j, 25.20 min and 4j, 25.70 min). LC-MS for
C25H28N2O3 (Mr = 404.5115): calcd. m/z [M+H]+ 405.51,
found 405.20 (3j, 10.60 min) and 405.20 (4j, 11.25 min). IR
(KBr) nmax/cm-1: 3468, 2926, 2851, 1751, 1645, 1591, 1513,
1386, 1300, 1248, 830; 1H NMR (CDCl3) d/ppm: 0.83 (s,
9H, C(CH3)3, 3j), 1.00 (s, 9H, C(CH3)3, 4j), 2.56-3.28 (m, 2
´ 2H, C3 and 2 ´1H, C2, THPO, 3j/4j), 3.74 (s, 3H, OCH3,
3j), 3.75 (s, 3H, OCH3, 4j), 4.40 (d, 2 ´ 1H, J = 1.56 Hz,
C4', b-lactam, 3j/4j), 4.82 (d, 1H, J = 1.89 Hz, C3',
b-lactam, 4j), 5.06 (d, 1H, J = 2.04 Hz, C3', b-lactam, 3j),
5.10 (d, 1H, J = 8.58 Hz, C5, THPO, 3j), 5.13 (d, 1H, J =
8.64 Hz, C5, THPO, 4j), 6.78 (d, 2H, J = 8.79 Hz, C3 and
C5, PMP, 3j), 6.81 (d, 2H, J = 8.64 Hz, C3 and C5, PMP,
4j), 7.11 (d, 2 ´ 1H, J = 7.74 Hz, C6, THPO, 3j/4j), 7.23 (d,
2H, J = 8.97 Hz, C2 and C6, PMP, 4j), 7.24 (d, 2H, J = 9.00
Hz, C2 and C6, PMP, 3j), 7.25-7.45 (m, 2 ´ 5H, Ph, 3j/4j);
13C NMR (CDCl3) d/ppm: 27.06 (C(CH3)3, 4j), 27.40
(C(CH3)3, 3j), 36.88 (C3, THPO, 4j), 36.92 (C3, THPO, 3j),
37.91 (C(CH3)3, 3j), 38.75 (C(CH3)3, 4j), 55.40 (OCH3, 3j),
55.41 (OCH3, 4j), 64.19 (C2, THPO, 3j), 66.14 (C2, THPO,
4j), 67.34 (C4', b-lactam, 4j), 69.29 (C4', b-lactam, 3j),
79.83 (C3', b-lactam, 4j), 80.24 (C3', b-lactam, 3j), 101.66
(C5, THPO, 3j), 102.44 (C5, THPO, 4j), 114.41 (C3 and C5,
PMP, 3j), 114.46 (C3 and C5, PMP, 4j), 119.04 (2 ´ C2 and
2 ´ C6, PMP, 3j/4j), 125.49 (C2 and C6, Ph, 4j), 126.48 (C2
and C6, Ph, 3j), 129.17 (C4, Ph, 4j), 129.32 (C4, Ph, 3j),
129.39 (C3 and C5, Ph, 3j), 129.64 (C3 and C5, Ph, 4j),
129.72 (C1, PMP, 3j), 129.79 (C1, PMP, 4j), 135.62 (C1, Ph,
3j), 135.85 (C1, Ph, 4j), 147.63 (C6, THPO, 3j), 147.83 (C6,
THPO, 4j), 156.66 (C4, PMP, 3j), 156.71 (C4, PMP, 4j),
161.57 (CO, b-lactam, 4j), 162.94 (CO, b-lactam, 3j),
191.68 (C4, THPO, 4j), 192.01 (C4, THPO, 4j).
(2R/2S)-2-Ferrocenyl-1-[trans-(3'R,4'R)-1'-
(4-methoxyphenyl)-2'-oxo-4'-phenylazetidin-3'-yl]-1,2,3,4-
tetrahydropyridin-4-one (3k/4k). – Obtained from (3R,4R)-1k
(30.0 mg, 6.46 × 10–2 mmol), diene 2a (13.8 mg, 7.11 × 10–2
mmol) and zinc(II) iodide (3.8 mg, 1.29 × 10–2 mmol) as a dia-
stereomeric mixture 3k/4k, 3.6 mg (11 %), Rf = 0.17 (eluens-
A). RP-HPLC analysis of diastereomeric mixture showed ra-
tio of 3k/4k – 85:15 % (3k, 25.57 min and 4k, 25.82 min).
LC-MS for C31H28FeN2O3 (Mr = 532.4251): calcd. m/z
[M+H]+ 533.43, found 533.00 (3k, 11.84 min) and 533.00
(4k, 12.11 min). IR (KBr) nmax/cm-1: 3448, 2928, 1750,
1638, 1590, 1513, 1299, 1249, 1224, 830; 1H NMR (CDCl3)
d/ppm: 3.03 (dd, 1H, J1 = 16.27 Hz, J2 = 5.16 Hz, C3,
THPO, 3k), 3.19 (dd, 1H, J1 = 16.31 Hz, J2 = 6.83 Hz, C3,
THPO, 3k), 2.98-3.22 (m, 2H, C3, THPO, 4k), 3.66 (m, 2 ´
1H, Fc, 3k/4k), 3.71 (s, 3H, OCH3, 3k), 3.75 (s, 3H, OCH3,
4k), 3.89 (m, 2 ´ 1H, Fc, 3k/4k), 4.03 (m, 2 ´ 1H, Fc,
3k/4k), 4.12 (s, 2 ´ 5H, Fc, 3k/4k), 4.15 (m, 2 ´ 1H, Fc,
3k/4k), 4.41 (d, 2 ´ 1H, J = 2.01 Hz, C4', b-lactam, 3k/4k),
4.40-4.47 (m, 2 ´ 1H, C2, THPO, 3k/4k), 4.49 (d, 1H, J =
1.80 Hz, C3', b-lactam, 3k), 4.59 (d, 1H, J = 2.01 Hz, C3',
b-lactam, 4k), 5.20 (d, 2 ´ 1H, J = 7.77 Hz, C5, THPO,
3k/4k), 6.73 (d, 2H, J = 7.14 Hz, C3 and C5, PMP, 3k), 6.78
(d, 2H, J = 9.12 Hz, C3 and C5, PMP, 4k), 6.96 (d, 2 ´ 1H, J
= 7.83 Hz, C6, THPO, 3k/4k), 7.03-7.10 (m, 2 ´ 2H, C3 and
C5, Ph, 3k/4k), 7.15 (d, 2 ´ 2H, J = 8.94 Hz, C2 and C6,
PMP, 3k/4k), 7.27-7.33 (m, 2 ´ 2H, C2 and C6, Ph, 3k/4k),
7.36-7.40 (m, 2 ´ 1H, C4, Ph, 3k/4k); 13C NMR (CDCl3)
d/ppm: 42.25 (C3, THPO, 3k), 42.97 (C3, THPO, 4k), 55.37
(2 ´ OCH3, 3k/4k), 57.16 (C4', b-lactam, 4k), 59.33 (C4',
b-lactam, 3k), 63.72 (C2, THPO, 4k), 65.18 (C2, THPO,
3k), 66.55 (3k/4k), 67.64 (4k), 68.05 (3k), 68.90 (5C, 3k),
68.99 (5C, 4k), 69.01 (3k), 69.12 (4k), 69.25 (3k), 69.33
(4k) (Fc), 75.39 (C3', b-lactam, 4k), 76.06 (C3', b-lactam,
3k), 85.74 (2 ´ C1, Fc, 3k/4k), 101.28 (C5, THPO, 3k),
101.58 (C5, THPO, 4k), 114.34 (C3 and C5, PMP, 3k),
114.39 (C3 and C5, PMP, 4k), 119.01 (2 ´ C2 and 2 ´ C6,
PMP, 3k/4k), 125.90 (C2 and C6, Ph, 4k), 126.78 (C2 and
C6, Ph, 3k), 128.96 (C3 and C5, Ph, 3k), 129.08 (C4, Ph,
3k), 129.22 (C4, Ph, 4k), 129.46 (C3 and C5, Ph, 4k),
129.76 (2 ´ C1, PMP, 3k/4k), 135.02 (2 ´ C1, Ph, 3k/4k),
147.05 (C6, THPO, 3k), 149.09 (C6, THPO, 4k), 156.64 (2
´ C4, PMP, 3k/4k), 162.11 (2 ´ CO, b-lactam, 3k/4k),
191.68 (C4, THPO, 3k), 191.76 (C4, THPO, 4k).
(2R/2S)-1-[trans-(3'R,4'R)-1',4'-bis(4-Methoxyphenyl)-2'-
oxoazetidin-3'-yl]-2-phenyl-1,2,3,4-tetrahydropyridin-4-one
(3l/4l). – Obtained from (3R,4R)-1l (20.0 mg, 5.17 × 10–2
mmol), diene 2b (12.9 mg, 5.69 × 10–2 mmol) and zinc(II)
iodide (3.2 mg, 1.04 × 10–2 mmol) as a diastereomeric mix-
ture 3l/4l, 13.6 mg (58 %), Rf = 0.19 (eluens-A). RP-HPLC
analysis of diastereomeric mixture showed ratio of 3l/4l –
68:32 % (3l, 24.34 min and 4l, 24.74 min). LC-MS for
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C28H26N2O4 (Mr = 454.5283): calcd. m/z [M+H]+ 455.53,
found 455.20 (3l, 10.44 min) and 455.20 (4l, 10.83 min). IR
(KBr) nmax/cm-1: 3467, 2918, 1750, 1591, 1513, 1457, 1300,
1249, 1179, 831; 1H NMR (CDCl3) d/ppm: 2.66 (dd, 1H, J1
= 16.56 Hz, J2 = 6.12 Hz, C3, THPO, 3l), 2.79 (dd, 1H, J1 =
16.44 Hz, J2 = 8.22 Hz, C3, THPO, 4l), 2.94 (dd, 1H, J1 =
16.44 Hz, J2 = 8.22 Hz, C3, THPO, 4l), 3.07 (dd, 1H, J1 =
16.56 Hz, J2 = 7.38 Hz, C3, THPO, 3l), 3.72 (s, 3H, OCH3,
3l), 3.73 (s, 3H, OCH3, 4l), 3.76 (s, 3H, OCH3, 3l), 3.80 (s,
3H, OCH3, 4l), 4.27 (d, 1H, J = 1.44 Hz, C3', b-lactam, 3l),
4.29 (s, 1H, C3', b-lactam, 4l), 4.59-4.63 (m, 2 ´ 1H, C2,
THPO, 3l/4l), 4.64 (s, 1H, C4', b-lactam, 3l), 4.69 (s, 1H,
C4', b-lactam, 4l), 5.20-5.25 (m, 2 ´ 1H, C5, THPO, 3l/4l),
6.66-6.72 (m, 2 ´ 2H, C3 and C5, PMP, 3l/4l), 6.72-6.78 (m,
2 ´ 2H, C3 and C5, PMP, 3l/4l), 6.85 (d, 1H, J = 8.46 Hz,
C6, THPO, 4l), 7.04 (d, 1H, J = 8.46 Hz, C6, THPO, 3l),
7.14-7.20 (m, 2 ´ 4H, C2 and C6, PMP, 3l/4l), 7.20-7.28 (m,
2 ´ 5H, Ph, 3l/4l), 7.30 (d, 2 ´ 2H, J = 7.98 Hz, C2 and
C6-Ph, 3l/4l); 13C NMR (CDCl3) d/ppm: 43.50 (C3, THPO,
3l), 43.57 (C3, THPO, 4l), 55.27 (OCH3, 3l), 55.34 (OCH3,
4l), 55.39 (2 ´ OCH3, 3l/4l), 61.42 (C2, THPO, 4l), 62.50
(C4', b-lactam, 4l), 64.12 (C2, THPO, 3l), 64.67 (C4',
b-lactam, 3l), 76.52 (C3', b-lactam, 4l), 76.97 (C3', b-lactam,
3l), 101.19 (C5, THPO, 3l), 102.28 (C5, THPO, 4l), 114.34
(C3 and C5, PMP, 3l), 114.36 (2 ´ C3 and 2 ´ C5. PMP,
3l/4l), 114.74 (C3 and C5, PMP, 4l), 119.00 (C2 and C6,
PMP, 4l), 119.03 (C2 and C6, PMP, 3l), 126.76 (2 ´ C1,
PMP, 3l/4l), 126.91 (C2 and C6, PMP, 4l), 126.99 (C2 and
C6, PMP, 3l), 127.07 (C2 and C6, Ph, 3l), 127.13 (C2 and
C6, Ph, 3l), 128.67 (C4, Ph, 4l), 128.70 (C4, Ph, 3l), 129.10
(C3 and C5, Ph, 4l), 129.22 (C3 and C5, Ph, 3l), 129.82 (2 ´
C1, PMP, 3l/4l), 137.84 (C1, Ph, 4l), 139.47 (C1, Ph, 3l),
148.69 (C6, THPO, 3l), 150.06 (C6, THPO, 4l), 156.64 (2 ´
C4, PMP, 3l/4l), 159.87 (2 ´ C4, PMP, 3l/4l), 161.72 (CO,
b-lactam, 4l), 161.82 (CO, b-lactam, 3l), 190.47 (C4, THPO,
4l), 190.57 (C4, THPO, 3l).
(2R/2S)-2-(4-Methoxyphenyl)-1-[trans-(3'R,4'R)-1',4'-
bis(4-methoxyphenyl)-2'-oxoazetidin-3'-yl]-1,2,3,4-
tetrahydropyridin-4-one (3m/4m). – Obtained from (3R,4R)-
1m (50.0 mg, 1.20 × 10–1 mmol), diene 2a (25.8 mg, 1.32 ×
10–1 mmol) and zinc(II) iodide (6.4 mg, 2.40 × 10–2 mmol)
as a diastereomeric mixture 3m/4m, 32.2 mg (55 %), Rf =
0.30 (eluens-A). RP-HPLC analysis of diastereomeric mix-
ture showed ratio of 3m/4m – 68:32 % (3m, 24.32 min and
4m, 24.71 min). LC-MS for C29H28N2O5 (Mr = 484.5547):
calcd m/z [M+H]+ 485.55, found 485.20 (3m, 10.40 min)
and 485.20 (4m, 10.79 min). IR (KBr) nmax/cm-1: 3467,
2918, 1750, 1591, 1513, 1457, 1300, 1249, 1179, 831;
1H NMR (CDCl3) d/ppm: 2.69 (dd, 1H, J1 = 16.56 Hz, J2 =
7.38 Hz, C3, THPO, 3m), 2.79 (dd, 1H, J1 = 16.44 Hz, J2 =
9.12 Hz, C3, THPO, 4m), 2.87 (dd, 1H, J1 = 16.38 Hz, J2 =
6.18 Hz, C3, THPO, 4m), 2.98 (dd, 1H, J1 = 16.56 Hz, J2 =
7.02 Hz, C3, THPO, 3m), 3.72 (s, 3H, OCH3, PMP, THPO,
3m), 3.73 (s, 3H, OCH3, PMP, THPO, 4m), 3.74 (s, 2 ´ 3H,
OCH3, PMP, 3m/4m), 3.75 (bs, 2 ´ 1H, C4', b-lactam,
3m/4m), 3.77 (s, 3H, OCH3, PMP, 3m), 3.80 (s, 3H, OCH3,
PMP, 4m), 4.26 (d, 1H, J = 1.80 Hz, C3', b-lactam, 4m),
4.27 (d, 1H, J = 1.62 Hz, C3', b-lactam, 3m), 4.56-4.58 (m, 2
´ 1H, C2, THPO, 3m/4m), 4.59 (d, 1H, J = 1.38 Hz, C4',
b-lactam, 3m), 4.64 (d, 1H, J = 1.38 Hz, C4', b-lactam, 4m),
5.22 (d, J = 7.86 Hz, 2 ´ 1H, C5, THPO, 3m/4m), 6.64-6.82
(m, 2 ´ 6H, C3 and C5, PMP, 3m/4m), 6.83 (d, 2 ´ 1H, J =
8.58 Hz, C6, THPO, 3m/4m), 7.04-7.28 (m, 2 ´ 6H, C2 and
C6, PMP, 3m/4m); 13C NMR (CDCl3) d/ppm: 43.61 (C3,
THPO, 3m), 43.76 (C3, THPO, 4m), 55.15 (OCH3, 3m),
55.22 (OCH3, 3m), 55.24 (OCH3, 4m), 55.32 (OCH3, 4m),
55.36 (OCH3, 3m), 55.38 (OCH3, 4m), 61.14 (C2, THPO,
4m), 62.59 (C4', b-lactam, 4m), 63.54 (C2, THPO, 3m),
64.78 (C4', b-lactam, 3m), 76.15 (C3', b-lactam, 4m), 76.52
(C3', b-lactam, 3m), 101.06 (C5, THPO, 3m), 102.22 (C5,
THPO, 4m), 114.27 (4m), 114.30 (3m), 114.33 (3m), 114.35
(4m), 114.46 (3m), 114.70 (4m) (C3 and C5, PMP), 118.98
(2 ´ C2 and 2 ´ C6, PMP, b-lactam, 3m/4m), 126.81 (2 ´
C1, PMP, b-lactam, 3m/4m), 127.15 (C2 and C6, PMP, C4',
b-lactam, 4m), 127.21 (C2 and C6, PMP, C4', b-lactam,
3m), 128.30 (C2 and C6, PMP, THPO, 4m), 128.40 (C2 and
C6, PMP, THPO, 3m), 129.82 (C1, PMP, THPO, 4m),
129.85 (C1, PMP, THPO, 3m), 131.12 (C1, PMP, C4',
b-lactam, 3m), 131.15 (C1, PMP, C4', b-lactam, 4m),
148.77 (C6, THPO, 3m), 149.99 (C6, THPO, 4m), 156.58
(C4, PMP, b-lactam, 3m), 156.60 (C4, PMP, b-lactam, 4m),
159.80 (2 ´ C4, PMP, C4', b-lactam, 3m/4m), 159.88 (2 ´
C4, PMP, THPO, 3m/4m), 161.79 (CO, b-lactam, 4m),
162.07 (CO, b-lactam, 3m), 186.96 (C4, THPO, 4m),
190.86 (C4, THPO, 3m).
(2R/2S)-1-[trans-(3'R,4'R)-1'-(4-Methoxyphenyl)-4'-(3,4-
dimethoxyphenyl)-2'-oxoazetidin-3'-yl]-2-phenyl-1,2,3,4-
tetrahydropyridin-4-one (3n/4n). – Obtained from (3R,4R)-
1n (20.0 mg, 4.80 × 10–2 mmol), diene 2a (10.3 mg, 5.28 ×
10–2 mmol) and zinc(II) iodide (3.2 mg, 9.60 × 10–3 mmol)
as a diastereomeric mixture 3n/4n, 17.6 mg (76 %), Rf =
0.24 (eluens-B). RP-HPLC analysis of diastereomeric mix-
ture showed ratio of 3n/4n – 66:34 % (3n, 23.04 min and 4n,
23.67 min). LC-MS for C29H28N2O5 (Mr = 484.5547): calcd.
m/z [M+H]+ 485.55, found 485.20 (3n, 9.32 min) and 485.20
(4n, 9.86 min). IR (KBr) nmax/cm-1: 3449, 2923, 1750,
1647, 1593, 1512, 1248, 1025, 831; 1H NMR (CDCl3)
d/ppm: 2.66 (dd, 1H, J1 = 16.51 Hz, J2 = 6.48 Hz, C3,
THPO, 3n), 2.80 (dd, 1H, J1 = 16.39 Hz, J2 = 8.43 Hz, C3,
THPO, 4n), 2.88-2.98 (m, 1H, C3, THPO, 4n), 3.06 (dd, 1H,
J1 = 16.48 Hz, J2 = 7.20 Hz, C3, THPO, 3n), 3.68 (s, 3H,
OCH3, 3n), 3.73 (s, 3H, OCH3, 4n), 3.74 (s, 2 ´ 3H, OCH3,
3n/4n), 3.84 (s, 3H, OCH3, 3n), 3.88 (s, 3H, OCH3, 4n),
4.33 (m, 2 ´ 1H, C3', b-lactam, 3n/4n), 4.64 (m, 2 ´ 1H, C2,
THPO and 2 ´ 1H, C4', b-lactam; 3n/4n), 5.23 (d, 2 ´ 1H, J
= 7.89 Hz, C5, THPO, 3n/4n), 6.27 (d, 1H, J = 1.80 Hz, C5,
3,4-(CH3O)2-Ph, 3n), 6.41 (dd, 2 ´ 1H, J1 = 8.19 Hz, J2 =
1.86 Hz, C6, 3,4-(CH3O)2-Ph, 3n/4n), 6.49 (d, 1H, J = 1.68
Hz, C5, 3,4-(CH3O)2-Ph, 4n), 6.69 (d, 1H, J = 8.25 Hz, C6,
THPO, 3n), 6.76 (d, 2 ´ 2H, J = 9.03 Hz, C3 and C5, PMP,
3n/4n), 6.83 (d, 1H, J = 8.22 Hz, C6, THPO, 4n), 7.12-7.33
(m, 2 ´ 5H, Ph and 2 ´ 2H, C2 and C6, PMP; 3n/4n); 13C
NMR (CDCl3) d/ppm: 43.46 (C3, THPO, 4n), 43.54 (C3,
THPO, 3n), 55.37 (2 ´ OCH3, 3n/4n), 55.88 (2 ´ OCH3,
3n), 55.94 (4n), 55.96 (4n), 61.43 (C2, THPO, 4n), 62.72
(C4', b-lactam, 4n), 64.06 (C2, THPO, 3n), 64.93 (C4',
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b-lactam, 3n), 76.29 (C3', b-lactam, 4n), 76.75 (C3',
b-lactam, 3n), 101.31 (C5, THPO, 3n), 102.38 (C5, THPO,
4n), 107.99 (C6, 3,4-(CH3O)2-Ph, 4n), 108.20 (C6, 3,4-
(CH3O)2-Ph, 3n), 111.26 (C5, 3,4-(CH3O)2-Ph, 3n), 111.47
(C5, 3,4-(CH3O)2-Ph, 4n), 114.32 (2 ´ C3 and 2 ´ C5, PMP,
3n/4n), 118.63 (C2, 3,4-(CH3O)2-Ph, 3n), 118.82 (C2,
3,4-(CH3O)2-Ph, 4n), 118.93 (C2 and C6, PMP, 4n), 118.97
(C2 and C6, PMP, 3n), 126.94 (C2 and C6, Ph, 4n), 127.00
(C2 and C6, Ph, 3n), 127.22 (C1, 3,4-(CH3O)2-Ph, 3n),
127.58 (C1, 3,4-(CH3O)2-Ph, 4n), 128.66 (2 ´ C4, Ph,
3n/4n), 129.11 (2 ´ C3 and 2 ´ C5, Ph, 3n/4n), 129.84 (2 ´
C1, PMP, 3n/4n), 137.79 (C1, Ph, 4n), 139.16 (C1, Ph, 3n),
148.65 (C6, THPO, 3n), 149.40 (C3 and C4,
3,4-(CH3O)2-Ph, 3n), 149.78 (C3 and C4, 3,4-(CH3O)2-Ph,
4n), 150.05 (C6, THPO, 4n), 156.64 (2 ´ C4, PMP, 3n/4n),
161.86 (CO, b-lactam, 4n), 161.95 (CO, b-lactam, 3n),
190.45 (C4, THPO, 3n), 190.60 (C4, THPO, 4n).
(2R/2S)-1-[trans-(3'R,4'R)-4'-(4-Fluorophenyl)-1'-(4-
methoxyphenyl)-2'-oxoazetidin-3'-yl]-2-phenyl-1,2,3,4-
tetrahydropyridin-4-one (3o/4o). – Obtained from (3R,4R)-1o
(20.0 mg, 5.34 × 10–2 mmol), diene 2b (12.9 mg, 5.87 × 10–2
mmol) and zinc(II) iodide (3.2 mg, 1.07 × 10–2 mmol) as a
diastereomeric mixture 3o/4o, 21.0 mg (89 %), Rf = 0.22
(eluens-A). RP-HPLC analysis of diastereomeric mixture
showed ratio of 3o/4o – 72:28 % (3o, 24.42 min and 4o,
24.77 min). LC-MS for C27H23FN2O3 (Mr = 442.4924):
calcd. m/z [M+H]+ 443.49, found 443.20 (3o, 10.59 min) and
443.20 (4o, 10.95 min). IR (KBr) nmax/cm-1: 3448, 2927,
1751, 1589, 1513, 1300, 1249, 831; 1H NMR (CDCl3)
d/ppm: 2.66 (dd, 1H, J1 = 16.50 Hz, J2 = 6.06 Hz, C3,
THPO, 3o), 2.80 (dd, 1H, J1 = 16.38 Hz, J2 = 8.70 Hz, C3,
THPO, 4o), 2.93 (dd, 1H, J1 = 16.44 Hz, J2 = 6.24 Hz, C3,
THPO, 4o), 3.07 (dd, 1H, J1 = 16.56 Hz, J2 = 7.44 Hz, C3,
THPO, 3o), 3.73 (s, 3H, OCH3, 3o), 3.74 (s, 3H, OCH3, 4o),
4.26 (bs, 1H, C3', b-lactam, 3o), 4.27 (bs, 1H, C3', b-lactam,
4o), 4.59 (t, 1H, J1,2 = 6.66 Hz, C2, THPO, 3o), 4.63 (t, 1H,
J1,2 = 7.56 Hz, C2, THPO, 4o), 4.66 (bs, 1H, C4', b-lactam,
3o), 4.69 (bs, 1H, C4', b-lactam, 4o), 5.24 (d, J = 7.86 Hz, 2
´ 1H, C5, THPO, 3o/4o), 6.68-6.72 (m, 2 ´ 1H, C6, THPO,
3o/4o), 6.74-6.77 (m, 2 ´ 2H, C3 and C5, PMP, 3o/4o), 6.87
(t, 2H, J1,2 = 8.34 Hz, C3 and C5, 4-F-Ph, 3o), 7.03 (t, 2H,
J1,2 = 8.34 Hz, C3 and C5, 4-F-Ph, 4o), 7.08-7.14 (m, 2 ´
2H, C2 and C6, 4-F-Ph, 3o/4o), 7.16-7.32 (m, 2 ´ 5H, Ph
and 2 ´ 2H, C2 and C6, PMP, 3o/4o); 13C NMR (CDCl3)
d/ppm: 43.45 (C3, THPO, 3o), 43.65 (C3, THPO, 4o), 55.40
(2 ´ OCH3, 3o/4o), 61.63 (C2, THPO, 4o), 62.06 (C4',
b-lactam, 4o), 64.28 (C2, THPO, 3o), 64.37 (C4', b-lactam,
3o), 76.50 (C3', b-lactam, 4o), 77.05 (C3', b-lactam, 3o),
101.38 (C5, THPO, 3o), 102.61 (C5, THPO, 4o), 114.41 (C3
and C5, PMP, 3o), 114.44 (C3 and C5, PMP, 4o), 116.02 (d,
J = 21.85 Hz, C3 and C5, p-F-Ph, 3o), 116.46 (d, J = 21,99
Hz, C3 and C5, p-F-Ph, 4o), 118.95 (C2 and C6, PMP, 4o),
118.97 (C2 and C6, PMP, 3o), 126.89 (C2 and C6, Ph, 4o),
126.98 (C2 and C6, Ph, 3o), 127.50 (d, J = 8.19 Hz, C2 and
C6, p-F-Ph, 3o), 127.57 (d, J = 10.40 Hz, C2 and C6,
p-F-Ph, 4o), 128.80 (C4, Ph, 4o), 128.82 (C4, Ph, 3o),
129.16 (C3 and C5, Ph, 4o), 129.31 (C3 and C5, Ph, 3o),
129.54 (2 ´ C1, PMP, 3o/4o), 130.71 (d, J = 2.64 Hz, 2 ´
C1, p-F-Ph, 3o/4o), 137.73 (C1, Ph, 4o), 139.60 (C1, Ph,
3o), 148.47 (C6, THPO, 3o), 149.89 (C6, THPO, 4o), 156.77
(2 ´ C4, PMP, 3o/4o), 161.58 (CO, b-lactam, 3o), 161.90
(CO, b-lactam, 4o), 163.54 (2 ´ C4, p-F-Ph, 3o/4o), 190.40
(C4, THPO, 3o), 190.58 (C4, THPO, 4o).
(2R/2S)-1-[trans-(3'R,4'R)-4'-(4-Trifluoromethylphenyl)-1'-
(4-methoxyphenyl)-2'-oxoazetidin-3'-yl]-2-phenyl-1,2,3,4-
tetrahydropyridin-4-one (3p/4p). – Obtained from (3R,4R)-1p
(20.0 mg, 4.71 × 10–2 mmol), diene 2b (12.9 mg, 5.18 × 10–2
mmol) and zinc(II) iodide (3.2 mg, 9.42 × 10–3 mmol) as a
diastereomeric mixture 3p/4p, 13.7 mg (59 %), Rf = 0.38
(eluens-A). RP-HPLC analysis of diastereomeric mixture
showed ratio of 3p/4p – 74:26 % (3p, 25.16 min and 4p,
25.48 min). LC-MS for C28H23F3N2O3 (Mr = 492.5003):
calcd. m/z [M+H]+ 493.50, found 493.20 (3p, 11.34 min)
and 493.20 (4p, 11.68 min). IR (KBr) nmax/cm-1: 3449,
1752, 1654, 1648, 1594, 1512, 1249, 830, 699; 1H NMR
(CDCl3) d/ppm: 2.67 (dd, 1H, J1 = 16.48 Hz, J2 = 6.18 Hz,
C3, THPO, 3p), 2.80 (m, 1H, C3, THPO, 4p), 2.93 (dd, 1H,
J1 = 16.39 Hz, J2 = 6.33 Hz, C3, THPO, 4p), 3.08 (dd, 1H,
J1 = 16.51 Hz, J2 = 7.44 Hz, C3, THPO, 3p), 3.73 (s, 3H,
OCH3, 3p), 3.74 (s, 3H, OCH3, 4p), 4.27 (d, 1H, J = 2.04
Hz, C3', b-lactam, 3p), 4.28 (d, 1H, J = 2.40 Hz, C3',
b-lactam, 3p), 4.58 (t, 1H, J1,2 = 6.75 Hz, C2, THPO, 3p),
4.64 (t, 1H, J1,2 = 8.60 Hz, C2, THPO, 4p), 4.72 (d, 1H, J =
1.83 Hz, C4', b-lactam, 3p), 4.74 (d, 1H, J = 1.95 Hz, C4',
b-lactam, 4p), 5.26 (d, 1H, J = 7.86 Hz, C5, THPO, 4p),
5.27 (d, 1H, J = 7.98 Hz, C5, THPO, 3p), 6.73-6.82 (m, 2 ´
2H, C3 and C5, PMP and 2 ´ 1H, C6, THPO, 3p/4p),
7.10-7.30 (m, 2 ´ 2H, C2 and C6, PMP, 2 ´ 2H, C2 and C6,
4-CF3-Ph and 2 ´ 5H, Ph, 3p/4p), 7.42 (d, 2H, J = 8.10 Hz,
C3 and C5, 4-CF3-Ph, 3p), 7.60 (d, 2H, J = 8.04 Hz, C3 and
C5, 4-CF3-Ph, 4p); 13C NMR (CDCl3) d/ppm: 43.38 (C3,
THPO, 3p), 43.69 (C3, THPO, 4p), 55.42 (2 ´ OCH3,
3p/4p), 55.78 (d, J = 358.59 Hz, 2 ´ CF3, 3p/4p), 61.70 (C2,
THPO, 4p), 62.02 (C4', b-lactam, 4p), 64.37 (C2, THPO,
3p), 64.43 (C4', b-lactam, 3p), 76.64 (C3', b-lactam, 4p),
77.14 (C3', b-lactam, 3p), 101.65 (C5, THPO, 3p), 102.94
(C5, THPO, 4p), 114.52 (C3 and C5, PMP, 3p), 114.55 (C3
and C5, PMP, 4p), 118.89 (C2 and C6, PMP, 4p), 118.92 (C2
and C6, PMP, 3p), 126.41 (d, J = 3.80 Hz, C3 and C5,
4-CF3-Ph, 3p), 126.08 (C2 and C6, Ph, 3p), 126.16 (C2 and
C6, Ph, 4p), 126.41 (d, J = 4.09 Hz, C3 and C5, 4-CF3-Ph,
4p), 126.87 (C2 and C6, 4-CF3-Ph, 4p), 127.00 (C2 and C6,
4-CF3-Ph, 3p), 128.92 (C4, Ph, 4p), 128.96 (C4, Ph, 3p),
129.21 (C3 and C5, Ph, 4p), 129.32 (C1, PMP, 4p), 129.35
(C1, PMP, 3p), 129.40 (C3 and C5, Ph, 3p), 137.62 (C1, Ph,
4p), 139.04 (2 ´ C1, 4-CF3-Ph, 3p/4p), 139.61 (C1, Ph, 3p),
143.38 (C4, 4-CF3-Ph, 3p), 143.40 (C4, 4-CF3-Ph, 4p),
148.26 (C6, THPO, 3p), 149.77 (C6, THPO, 4p), 156.91 (2
´ C4, PMP, 3p/4p), 161.33 (2 ´ CO, b-lactam, 3p/4p),
190.37 (2 ´ C4, THPO, 3p/4p).
(2R/2S)-1-[trans-(3'R,4'R)-4'-Ferrocenyl-1'-(4-
methoxyphenyl)-2'-oxoazetidin-3'-yl]-2-phenyl-1,2,3,4-
tetrahydropyridin-4-one ((2R,3'R,4'R)-3q/(2S,3'R,4'R)-4q). –
Obtained from (3R,4R)-1q (30.0 mg, 6.46 × 10–2 mmol),
diene 2a (13.8 mg, 7.11 × 10–2 mmol) and zinc(II) iodide
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(3.8 mg, 1.29 × 10–2 mmol) as a diastereomeric mixture
3q/4q, 29.0 mg (84 %), Rf = 0.17 (eluens-A). RP-HPLC
analysis of diastereomeric mixture showed ratio of 3q/4q –
80:20 % (3q, 25.07 min and 4q, 25.46 min). LC-MS for
C31H28FeN2O3 (Mr = 532.4251): calcd. m/z [M+H]+ 533.43,
found 533.00 (3q, 11.35 min) and 533.00 (4q, 11.78 min). IR
(KBr) nmax/cm-1: 3394, 1736, 1702, 1686, 1654, 1648, 1637,
1618, 1560, 1458, 699; 1H NMR (CDCl3) d/ppm: 2.68-2.88
(m, 2 ´ 1H, C3, THPO, 3q/4q), 2.95-3.12 (m, 2 ´ 1H, C3,
THPO, 3q/4q), 3.79 (s, 2 ´ 3H, OCH3, 3q/4q), 3.96 (s, 5H,
Fc, 3q), 4.01 (s, 5H, Fc, 4q), 4.06-4.10 (m, 2 ´ 3H, Fc,
3q/4q), 4.14 (m, 2 ´ 1H, Fc, 3q/4q), 4.53 (d, 1H, J = 2.07
Hz, C4', b-lactam, 3q), 4.56 (d, J = 2.01 Hz, 1H, C4',
b-lactam, 4q), 4.71 (d, 1H, J = 2.13 Hz, C3', b-lactam, 4q),
4.81 (m, 1H, C2, THPO, 4q), 4.86 (d, J = 2.01 Hz, 1H, C3',
b-lactam, 3q), 4.96 (m, 1H, C2, THPO, 3q), 5.22-5.29 (m, 2
´ 1H, C5, THPO, 3q/4q), 6.84-6.90 (m, 2 ´ 2H, C3 and C5,
PMP and 2 ´ 1H, C6, THPO, 3q/4q), 7.20-7.52 (m, 2 ´ 2H,
C2 and C6, PMP and 2 ´ 5H, Ph, 3q/4q); 13C NMR (CDCl3)
d/ppm: 43.67 (C3, THPO, 4q), 44.80 (C3, THPO, 3q), 55.42
(2 ´ OCH3, 3q/4q), 58.81 (C2, THPO, 3q), 59.01 (C2,
THPO, 4q), 61.15 (C4', b-lactam, 4q), 63.04 (C4',
b-lactam, 3q), 65.86 (4q), 65.98 (3q), 68.02 (3q), 68.05
(3q), 68.21 (4q), 68.47 (4q), 68,54 (5C, 4q), 68.59 (5C, 3q),
68.74 (3q) and 68.95 (4q) (Fc), 74.56 (C3', b-lactam, 3q),
75.49 (C3', b-lactam, 4q), 84.21 (2 ´ C1, Fc, 3q/4q), 101.59
(C5, THPO, 4q), 101.92 (C5, THPO, 3q), 114.31 (2 ´ C3
and 2 ´ C5, PMP, 3q/4q), 120.39 (2 ´ C2 and 2 ´ C6, PMP,
3q/4q), 126.71 (C2 and C6, Ph, 4q), 127.40 (C2 and C6, Ph,
3q), 128.71 (C4, Ph, 4q), 128.91 (C4, Ph, 3q), 129.26 (C3
and C5, Ph, 3q), 129.36 (C3 and C5, Ph, 4q), 129.39 (2 ´
C1, PMP, 3q/4q), 138.30 (2 ´ C1, Ph, 3q/4q), 149.53 (C6,
THPO, 3q), 150,55 (C6, THPO, 4q), 157.05 (2 ´ C4, PMP,
3q/4q), 162.59 (2 ´ CO, b-lactam, 3q/4q), 190.64 (2 ´ C4,
THPO, 3q/4q).
(2S/2R)-1-[trans-(3'S,4'S)-4'-Ferrocenyl-1'-(4-
methoxyphenyl)-2'-oxoazetidin-3'-yl]-2-phenyl-1,2,3,4-
tetrahydropyridin-4-one ((2S,3'S,4'S)-3q/(2R,3'S,4'S)-4q). –
Obtained from (3S,4S)-1q (20.0 mg, 4.31 × 10–2 mmol),
diene 2a (8.6 mg, 4.74 × 10–2 mmol) and zinc(II) iodide (2.6
mg, 8.61 × 10–3 mmol) as a diastereomeric mixture 3q/4q,
18.1 mg (79 %), Rf = 0.17 (eluens-A). RP-HPLC analysis of
diastereomeric mixture showed ratio of 3q/4q – 80:20 % (3q,
25.07 min and 4q, 25.46 min). LC-MS for C31H28FeN2O3
(Mr = 532.4251): calcd. m/z [M+H]+ 533.43, found 533.00
(3q, 11.37 min) and 533.00 (4q, 11.79 min). Diastereomeric
mixture of 3q/4q was separated by a preparative thin layer
chromatography using eluens-A.
(2S)-1-[trans-(3'S,4'S)-4'-Ferrocenyl-1'-(4-methoxyphenyl)-
2'-oxoazetidin-3'-yl]-2-phenyl-1,2,3,4-tetrahydropyridin-4-one
((2S,3'S,4'S)-3q). – 14.48 mg, m.p. 183-184 oC; [a]D =
+56,8 (c = 0.35 g/100 mL dichloromethane); IR (KBr)
nmax/cm-1: 3448, 1752, 1654, 1593, 1511, 1458, 1249, 1027,
799; 1H NMR (CDCl3) d/ppm: 2.81 (dd, 1H, J1 = 16.51 Hz,
J2 = 7.20 Hz, C3, THPO), 3.06 (dd, 1H, J1 = 16.51 Hz, J2 =
6.60 Hz, C3, THPO), 3.70 (m, 1H, Fc), 3.76 (m, 1H, Fc),
3.79 (s, 3H, OCH3), 3.96 (s, 5H, Fc), 4.05-4.10 (m, 2H, Fc),
4.53 (bs, 1H, C4', b-lactam), 4.86 (bs, 1H, C3', b-lactam),
4.81 (t, 1H, J1,2 = 7.20 Hz, C2, THPO), 5.28 (d, 1H, J = 9.60
Hz, C5, THPO), 6.87 (d, 2H, J = 8.10 Hz, C3 and C5, PMP),
7.24 (d, 1H, J = 8.82 Hz, C6, THPO), 7.30 (d, 2H, J = 8.40
Hz, C2 and C6, PMP), 7.36-7.52 (m, 5H, Ph); 13C NMR
(CDCl3) d/ppm: 43.77 (C3, THPO), 55.49 (OCH3), 58.85
(C2, THPO), 66.06 (C4', b-lactam), 68.07, 68.10, 68.61,
68.65 and 68.79 (Fc), 74.64 (C3', b-lactam), 84.35 (C1, Fc),
102.08 (C5, THPO), 114.41 (C3 and C5, PMP), 120.46 (C2
and C6, PMP), 127.50 (C2 and C6, Ph), 128.96 (C4, Ph),
129.31 (C3 and C5, Ph), 129.53 (C1, PMP), 138.43 (C1, Ph),
149.45 (C6, THPO), 157.17 (C4, PMP), 162.66 (CO,
b-lactam), 190.62 (C4, THPO).
(2R)-1-[trans-(3'S,4'S)-4'-Ferrocenyl-1'-(4-methoxyphenyl)-
2'-oxoazetidin-3'-yl]-2-phenyl-1,2,3,4-tetrahydropyridin-4-one
((2R,3'S,4'S)-4q). – 3.62 mg; IR (KBr) nmax/cm-1: 3448,
1752, 1654, 1593, 1511, 1458, 1249, 1027, 799; 1H NMR
(CDCl3) d/ppm: 2.75 (dd, 1H, J1 = 16.51 Hz, J2 = 6.60 Hz,
C3, THPO), 3.08 (dd, 1H, J1 = 16.51 Hz, J2 = 6.90 Hz, C3,
THPO), 3.79 (s, 3H, OCH3), 3.90 (m, 1H, Fc), 3.96 (m, 1H,
Fc), 4.01 (s, 5H, Fc), 4.14 (m, 2H, Fc), 4.56 (d, 1H, J = 2.10
Hz, C4', b-lactam), 4.71 (d, 1H, J = 2.10 Hz, C3', b-lactam),
4.81 (t, 1H, J1,2 = 6.90 Hz, C2, THPO), 5.25 (d, 1H, J = 9.60
Hz, C5, THPO), 6.86 (d, 2H, J = 9.00 Hz, C3 and C5, PMP),
7.22-7.32 (m, 1H, C6, THPO and 2H, C2 and C6, PMP),
7.36-7.50 (m, 5H, Ph); 13C NMR (CDCl3) d/ppm: 44.99 (C3,
THPO), 59.12 (OCH3), 61.28 (C2, THPO), 65.93 (C4',
b-lactam), 68.25, 68.48, 68.65 and 68.98 (Fc), 75.64 (C3',
b-lactam), 84.35 (C1, Fc), 101.72 (C5, THPO), 114.41 (C3
and C5, PMP), 120.50 (C2 and C6, PMP), 126.80 (C2 and
C6, Ph), 128.75 (C4, Ph), 129.41 (C3 and C5, Ph), 129.53
(C1, PMP), 138.43 (C1, Ph), 150.48 (C6, THPO), 157.17
(C4, PMP), 162.66 (CO, b-lactam), 190.62 (C4, THPO).
(2R/2S)-1-[trans-(3'R,4'R)-2'-Oxo-4'-phenylazetidin-3'-yl]-
2-phenyl-1,2,3,4-tetrahydropyridin-4-one (3s/4s). – Ob-
tained from (3R,4R)-1s (15.0 mg, 5.99 × 10–2 mmol), diene
2b (15.0 mg, 6.59 × 10–2 mmol) and zinc(II) iodide (3.8
mg, 1.20 × 10–2 mmol) as a diastereomeric mixture 3s/4s,
9.52 mg (50 %), Rf = 0.20 (eluens-B). RP-HPLC analysis of
diastereomeric mixture showed ratio of 3s/4s – 66:34 %
(3s, 23.80 min and 4s, 24.10 min). LC-MS for C20H18N2O2
(Mr = 318.3772): calcd. m/z [M+H]+ 319.38, found 319.20
(3s, 9.25 min) and 319.20 (4s, 9.46 min). IR (KBr)
nmax/cm-1: 3087, 2918, 1774, 1622, 1566, 1229, 1199, 699;
1H NMR (CDCl3) d/ppm: 2.65 (dd, 1H, J1 = 16.51 Hz, J2 =
6.90 Hz, C3, THPO, 3s), 2.76 (dd, 1H, J1 = 16.51 Hz, J2 =
8.10 Hz, C3, THPO, 4s), 2.95 (m, 1H, C3, THPO, 4s), 3.00
(dd, 1H, J1 = 16.51 Hz, J2 = 6.90 Hz, C3, THPO, 3s), 4.21
(m, 2 ´ 1H, C4', b-lactam, 3s/4s), 4.44 (d, 1H, J = 1.80 Hz,
C3', b-lactam, 3s), 4.49 (d, 1H, J = 1.80 Hz, C3', b-lactam,
4s), 4.59 (t, 1H, J1,2 = 6.90 Hz, C2, THPO, 3s), 4.62 (m,
1H, C2, THPO, 4s), 5.24 (m, 2 ´ 1H, C5, THPO, 3s/4s),
6.42 (bs, 2 ´ 1H, NH, 3s/4s), 6.81 (d, 2 ´ 1H, J = 6.60 Hz,
C6, THPO, 3s/4s), 7.10-7.35 (m, 2 ´ 10H, 2 ´ Ph, 3s/4s);
13C NMR (CDCl3) d/ppm: 43.54 (C3, THPO, 3s), 43.63
(C3, THPO, 4s), 59.17 (C2, THPO, 4s), 61.28 (C2, THPO,
3s), 61.38 (C4', b-lactam, 4s), 64.07 (C4', b-lactam, 3s),
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77.65 (C3', b-lactam, 4s), 77.86 (C3', b-lactam, 3s), 101.37
(C5, THPO, 3s), 102.38 (C5, THPO, 4s), 125.42 (C2 and
C6, Ph, b-lactam, 4s), 125.44 (C2 and C6, Ph, b-lactam,
3s), 126.78 (C2 and C6, Ph, THPO, 4s), 126.96 (C2 and
C6, Ph, THPO, 3s), 128.65 (C4, Ph, b-lactam, 4s), 128.71
(C4, Ph, THPO, 3s and C3 and C5, Ph, b-lactam, 4s),
128.76 (C3 and C5, Ph, b-lactam, 3s), 128.96 (C4, Ph,
THPO, 4s), 129.13 (C3 and C5, Ph, THPO, 4s and C4, Ph,
THPO, 3s), 129.19 (C3 and C5, Ph, THPO, 3s), 136.76
(C1, Ph, b-lactam, 3s), 137.17 (C1, Ph, b-lactam, 4s),
137.68 (C1, Ph, THPO, 4s), 139.16 (C1, Ph, THPO, 3s),
148.78 (C6, THPO, 3s), 150.08 (C6, THPO, 4s), 165.51
(CO, b-lactam, 4s), 165.77 (CO, b-lactam, 3s), 190.56 (C4,
THPO, 3s), 190.59 (C4, THPO, 4s).
CONCLUSIONS
The study demonstrates the asymmetric approach in the
synthesis of pyridin-4-one ring attached to the b-lactam
ring via C-N bond, using the chirality and functionali-
sation of the homochiral amino-b-lactam nucleus as the
building block and stereocontrolling element.
The study was focused on the aza-Diels – Alder re-
action of azetidin-2-one-tethered imines with siloxydie-
nes performed in the presence of Lewis acid. First the
effect of the amount of various catalysts, equimolar (x =
100 %) and a catalytic (x = 20 %), on the coversion rate
and as well as on the product ratio was studied. The
cycloaddition at low temperature (–20 °C) in acetonitrile
under zinc(II) iodide (x = 20 %) catalysis provided the
best chemical yield (92 %) combined with the highest dia-
stereoselectivity (68:32). Furthermore, the influence of
various groups on azetidin-2-one-tethered imines (R1 =
H, PMP; R2 = aryl, ferrocenyl; R3 = alkyl, aryl, ferro-
cenyl) and on diene (TMS, TBDMS, (-)- and (+)-menthyl,
(-)-trans-2-phenyl-1-cyclohexyl) have been applied in
cycloaddition reaction leading to the formation of two
stereoisomers of 2-aryl(alkyl)-2,3-dihydro-4-pyridones
with diastereomeric ratio varying from 86:14 to 55:45.
The crystal structure of compound (2S,3'S,4'S)-3q was
determined in order to establish unambiguously both ab-
solute and relative configuration at the stereogenic cen-
ter C21 of the pyridin-4-one ring and the absolute con-
figuration of C21 found to be S.
Semiempirical PM3 calculation method was used to
model Diels – Alder reaction of dienes with azetidin-2-
one-tethered imines catalyzed by Lewis acids. FMO
analysis has revealed that the preferred regioselectivity
is governed by orbital symmetry and the size of coeffi-
cients. It was assumed that for Lewis acid (zinc(II) io-
dide), azetidin-2-one-tethered imine acts as a bidentate
ligand, coordinating with metal via imine nitrogen and
carbonyl oxygen. PM3 modelling has shown a slight
preference to diene approach from the top side yielding
R-isomer, while diene approach from the bottom side
leading to S-isomer is less preferred. These computatio-
nal predictions are in good agreement with experimental
results, where in the most of Lewis acid catalyzed reac-
tions, R:S ratio ≈70:30 is found.
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SA@ETAK
Studija asimetri~ne sinteze 2-aril(alkil)-2,3-dihidro-4-piridona aza-Diels – Alderovom reakcijom
imina, izvedenih iz aminoazetidin-2-ona, i siloksidiena kataliziranom Lewisovim kiselinama
Tanja Poljak, Kre{imir Mol~anov, Davor Margeti} i Ivan Habu{
Ispitani su trans-3-amino-b-laktami kao kiralne gra|evne jedinice u asimetri~noj sintezi 2-aril(alkil)-2,3-
dihidro-4-piridona aza-Diels – Alderovom reakcijom imina, izvedenih iz aminoazetidin-2-ona, i siloksidiena
kataliziranom Lewisovim kiselinama.
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Crystallographic Data for the Compound (2S,3'S,4'S)-3q
SUPPLEMENT
to article: Study on the Lewis Acid-promoted Aza-Diels – Alder Reaction
of Azetidin-2-one-tethered Imines with Siloxydienes in the Asymmetric Synthesis
of 2-Aryl(alkyl)-2,3-dihydro-4-pyridones
by Tanja Poljak, Kre{imir Mol~anov, Davor Margeti}, and Ivan Habu{
Crystals of compound (2S,3'S,4'S)-3q were prepared by
liquid-liquid diffusion using dichloromethane solution
and hexane (1 mL : 5 mL). Crystal size and quality pro-
hibited use of MoKa radiation, so CuKa (1.54179 Å) had
to be used for single crystal measurement, despite high
absorption coefficient of iron atoms.
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Table I. Crystallographic data and structure refinement data for
compound (2S,3'S,4'S)-3q
Empirical formula C31H27O3N2Fe
Formula wt. / g mol–1 531.41
Crystal dimensions / mm 0.29 × 0.07 × 0.05
Space group P 21
a / Å 11.4773(6)
b / Å 7.4679(7)
c / Å 15.6163(14)
a / ° 90
b / ° 105.925(6)
g / ° 90
Z 2
V / Å3 1287.12(18)
Dcalc / g cm-3 1.371
m / mm–1 4.982
Q range / ° 2.94 – 76.25
Range of h, k, l –14 > h > 0; –9 > k > 0;
–18 > l > 19
Reflections collected 3056
Independent reflections 2913
Observed reflections (I ≥ 2s) 1272
Rint 0.078
R (F) 0.079
Rw (F
2) 0.1972
Goodness of fit 1.002
Drmax, Drmin (eÅ–3) 0.396; –0.458
Table II. Selected torsion angles (in degrees) defining conforma-
tion of (2S,3'S,4'S)-3q
N2 – C12 – C13 – O1 57(2)
N2 – C12 – C13 – N1 –126.8(11)
N2 – C12 – C11 – C1 118.4(12)
N2 – C12 – C11 – N1 –124.3(11)
C12 – C13 – N1 – C11 3.0(10)
C12 – C13 – N1 – C14 –170.4(13)
O1 – C13 – N1 – C14 7(2)
O1 – C13 – N1 – C11 –179.8(14)
O1 – C13 – C12 – C11 –179.5(18)
N1 – C11 – C12 – C13 2.7(9)
C11 – C12 – C13 – N1 –2.8(9)
C14 – N1 – C11 – C1 –54.0(17)
C14 – N1 – C11 – C12 –170.5(12)
C1 – C11 – N1 – C13 –119.4(11)
C1 – C11 – C12 – C13 120.0(11)
C12 – C11 – N1 – C13 –2.9(10)
C19 – C14 – N1 – C13 10(2)
C19 – C14 – N1 – C11 –161.1(12)
C15 – C14 – N1 – C13 –165.9(13)
C15 – C14 – N1 – C11 23(2)
C21 – N2 – C12 – C13 –52.1(15)
C21 – N2 – C12 – C11 51.5(16)
C25 – N2 – C12 – C13 –114.7(12)
C25 – N2 – C12 – C11 –141.7(11)
Data collection was performed on an Enraf Nonius
CAD4 diffractometer at room temperature [293(2) K].
The WinGX standard procedure was applied for data re-
duction.1 Three standard reflections were measured eve-
ry 120 minutes as intensity control. Absorption correc-
tion based on eight Y-scan reflexions was performed.2
The structure was solved with SHELXS973 and refined
with SHELXL97.4 The models were refined using the
full matrix least squares refinement. Hydrogen atoms
were refined as riding entities. The atomic scattering
factors were those included in SHELXL97.4 Molecular
geometry calculations were performed with PLATON,5
and molecular graphics were prepared using ORTEP-36
and CCDC-Mercury.7
Absolute configurations of C11 and C12 atoms were
known from a previously prepared compound,8 and the
absolute configuration of the C21 atom was determined
in relation to them.
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Table III. Bond lengths (in Å) and bond angles (in degrees) in the
azetidin-2-one ring
N2 – C12 1.433(13)
C11 – C12 1.563(15)
C1 – C11 1.526(15)
C11 – N1 1.477(14)
N1 – C14 1.416(14)
N1 – C13 1.391(14)
C13 – C12 1.547(16)
C13 – O1 1.205(14)
N2 – C12 – C11 121.7(10)
C12 – C11 – C1 114.6(10)
C12 – C11 – N1 88.1(8)
C1 – C11 – N1 115.6(10)
C11 – N1 – C14 132.2(10)
C11 – N1 – C13 94.6(9)
C14 – N1 – C13 132.8(11)
N1 – C13 – O1 129.1(12)
N1 – C13 – C12 91.9(9)
O1 – C13 – C12 138.9(12)
C13 – C12 – N2 119.2(9)
C13 – C12 – C11 85.3(9)
Table IV. Geometric parameters of the hydrogen bonds
D-H···A / Å D-H / Å H···A / Å D-H···A / ° Symm. operation on A
C22-H22B···O1 3.391(15) 0.97 2.43 171 x, -1+y, z
C25-H25···O3 3.363(16) 0.93 2.45 167 -x, ½+y, 2-z
C30-H30···O3 3.274(18) 0.93 2.57 132 1-x, ½+y, 2-z
Table V. Geometric parameters of the C-H···p interactions
H···Cg / Å g / ° C-H···Cg / ° C···Cg / Å Symm. op. on Cg
C20-H20c···Cg(C14→C19) 2.79 12.85 152 3.670(17) 1 – x, ½ + y, 2 – z
C20-H20B···Cg(C26→C31) 3.25 25.13 146 4.078(14) 1 – x, ½ + y, 2 – z
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